Literatur

Abdul-Rahim AH, Shen L, Rush CJ, et al. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction. Eur J Heart Fail 2018; 20(7):1139–45. DOI: 10.1002/ejhf.1160. http://www.ncbi.nlm.nih.gov/pubmed/29493058.
Abraham WT, Stevenson LW, Bourge RC, et al. Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: Complete follow-up results from the CHAMPION randomised trial. Lancet 2016; 387(10017):453–61. DOI: 10.1016/S0140-6736(15)00723-0. http://www.ncbi.nlm.nih.gov/pubmed/26560249.
Abraham WT, Zile MR, Weaver FA, et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Heart Fail 2015; 3(6):487–96. DOI: 10.1016/j.jchf.2015.02.006. http://www.ncbi.nlm.nih.gov/pubmed/25982108.
Acker MA, Parides MK, Perrault LP, et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 2014; 370(1):23–32. DOI: 10.1056/NEJMoa1312808. http://www.ncbi.nlm.nih.gov/pubmed/24245543.
Afshar K, Feichtner A, Boyd K, et al. Systematic development and adjustment of the German version of the Supportive and Palliative Care Indicators Tool (SPICT-DE). BMC Palliat Care 2018; 17(1):27. DOI: 10.1186/s12904-018-0283-7. http://www.ncbi.nlm.nih.gov/pubmed/29454343.
Afshar K, Müller-Mundt G, Schneider N. Wie können Patienten mit chronisch fortschreitenden nicht-onkologischen Erkrankungen erkannt werden, bei denen eine Palliativversorgung sinnvoll ist? Z Palliativmed 2016; 17(03):133–8. DOI: 10.1055/s-0042-103176.
Agrawal RP, Choudhary R, Sharma P, et al. Glyceryl trinitrate spray in the management of painful diabetic neuropathy: A randomized double blind placebo controlled cross-over study. Diabetes Res Clin Pract 2007; 77(2):161–7. http://www.ncbi.nlm.nih.gov/pubmed/17316865.
Ahmed A, Rich MW, Fleg JL, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: The ancillary digitalis investigation group trial. Circulation 2006; 114(5):397–403. DOI: 10.1161/CIRCULATIONAHA.106.628347. http://www.ncbi.nlm.nih.gov/pubmed/16864724.
Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: A comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27(2):178–86. http://www.ncbi.nlm.nih.gov/pubmed/16339157.
Alba AC, Rao V, Ivanov J, et al. Usefulness of the INTERMACS scale to predict outcomes after mechanical assist device implantation. J Heart Lung Transplant 2009; 28(8):827–33. DOI: 10.1016/j.healun.2009.04.033. http://www.ncbi.nlm.nih.gov/pubmed/19632580.
Albus C, Waller C, Fritzsche K, et al. Bedeutung von psychosozialen Faktoren in der Kardiologie – Update 2018: Positionspapier der Deutschen Gesellschaft für Kardiologie. Der Kardiologe 2018; 131(4):339. DOI: 10.1007/s12181-018-0271-4.
Allen LA, Hernandez AF, Peterson ED, et al. Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. Circ Heart Fail 2011; 4(3):293–300. DOI: 10.1161/CIRCHEARTFAILURE.110.959171. http://www.ncbi.nlm.nih.gov/pubmed/21447803.
Allen LA, O‘Connor CM. Management of acute decompensated heart failure. CMAJ 2007; 176(6):797–805. http://www.ncbi.nlm.nih.gov/pubmed/17353535.
Alon D, Stein GY, Korenfeld R, et al. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS. One. 2013; 8(8):e72476. DOI: 10.1371/journal.pone.0072476. http://www.ncbi.nlm.nih.gov/pubmed/24009684.
Alsheikh-Ali AA, Homer M, Maddukuri PV, et al. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2008; 19(8):784–9. DOI: 10.1111/j.1540-8167.2008.01111.x. http://www.ncbi.nlm.nih.gov/pubmed/18284493.
Alt-Epping B. Klug entscheiden: . in der Palliativmedizin. Vor den Rahmenbedingungen von Endlichkeit und komplexer Belastung sind die Behandlungsziele auf die bestmögliche Symptomlinderung und umfassende Unterstützung zu richten. Dtsch Arztebl 2016; 113(42):A-1870-2. https://www.aerzteblatt.de/archiv/183068/Klug-entscheiden-in-der-Palliativmedizin.
Ambrosy AP, Braunwald E, Morrow DA, et al. Angiotensin Receptor-Neprilysin Inhibition Based on History of Heart Failure and Use of Renin-Angiotensin System Antagonists. J Am Coll Cardiol 2020; 76(9):1034–48. DOI: 10.1016/j.jacc.2020.06.073. http://www.ncbi.nlm.nih.gov/pubmed/32854838.
American College of Cardiology (ACC), American Geriatrics Society (AGS), American Academy of Hospice and Palliative Medicine (AAHPM), et al. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7(7):1008–26. DOI: 10.1016/j.hrthm.2010.04.033. http://www.ncbi.nlm.nih.gov/pubmed/20471915.
Ampadu J, Morley JE. Heart failure and cognitive dysfunction. Int J Cardiol 2015; 178:12–23. DOI: 10.1016/j.ijcard.2014.10.087. http://www.ncbi.nlm.nih.gov/pubmed/25464210.
Anand IS, Kalra GS, Harris P, et al. Diuretics as initial and sole treatment in chronic cardiac failure. Cardioscience 1991; 2(4):273–8. http://www.ncbi.nlm.nih.gov/pubmed/1760518.
Anderson L, Sharp GA, Norton RJ, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev 2017; 6:CD007130. DOI: 10.1002/14651858.CD007130.pub4. http://www.ncbi.nlm.nih.gov/pubmed/28665511.
Angermann CE, Gelbrich G, Störk S, et al. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial. JAMA 2016; 315(24):2683–93. DOI: 10.1001/jama.2016.7635. http://www.ncbi.nlm.nih.gov/pubmed/27367876.
Angermann CE, Stork S, Gelbrich G, et al. Mode of action and effects of standardized collaborative disease management on mortality and morbidity in patients with systolic heart failure: The Interdisciplinary Network for Heart Failure (INH) study. Circ Heart Fail 2012; 5(1):25–35. DOI: 10.1161/CIRCHEARTFAILURE.111.962969. http://www.ncbi.nlm.nih.gov/pubmed/21956192.
Angermann CE. Comorbidities in Heart Failure: A Key Issue. Eur J Heart Fail 2009; 8(Suppl 1):i5-i10.
Anker SD, Butler J, Filippatos G, et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation 2021; 143(4):337–49. DOI: 10.1161/CIRCULATIONAHA.120.051824. http://www.ncbi.nlm.nih.gov/pubmed/33175585.
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021; 385(16):1451–61. DOI: 10.1056/NEJMoa2107038. http://www.ncbi.nlm.nih.gov/pubmed/34449189.
Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361(25):2436–48. DOI: 10.1056/NEJMoa0908355. http://www.ncbi.nlm.nih.gov/pubmed/19920054.
Anker SD, Kirwan B-A, van Veldhuisen DJ, et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: An individual patient data meta-analysis. Eur J Heart Fail 2018; 20(1):125–33. DOI: 10.1002/ejhf.823. http://www.ncbi.nlm.nih.gov/pubmed/28436136.
Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349(9058):1050–3. http://www.ncbi.nlm.nih.gov/pubmed/9107242.
Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: A systematic review. JBI Database System Rev Implement Rep 2018; 16(1):140–232. DOI: 10.11124/JBISRIR-2017-003382. http://www.ncbi.nlm.nih.gov/pubmed/29324562.
Apóstolo J, Cooke R, Bobrowicz-Campos E, et al. Predicting risk and outcomes for frail older adults: An umbrella review of frailty screening tools. JBI Database System Rev Implement Rep 2017; 15(4):1154–208. DOI: 10.11124/JBISRIR-2016-003018. http://www.ncbi.nlm.nih.gov/pubmed/28398987.
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)-Ständige Kommission Leitlinien. AWMF-Regelwerk Leitlinien: Version 2.0. 2020 [cited: 2021-03-22]. http://www.awmf.org/leitlinien/awmf-regelwerk.html.
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV), Deutsche Adipositas-Gesellschaft (DAG). S3-Leitlinie: Chirurgie der Adipositas und metabolischer Erkrankungen. 2018 [cited: 2019-03-06]. https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_Chirurgie-Adipositas-metabolische-Erkrankugen_2018-02.pdf.
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Suchtforschung und Suchttherapie (DG-Sucht), et al. S3-Leitlinie Screening, Diagnostik und Behandlung des schädlichen und abhängigen Tabakkonsum: Registernummer 076-006, Version 2015-02. 2014 [cited: 2021-06-23]. http://www.awmf.org/leitlinien/detail/ll/076-006.html.
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Encke A, Haas S, et al. S3-Leitlinie Prophylaxe der venösen Thromboembolie (VTE). 2015 [cited: 2016-06-30]. http://www.awmf.org/uploads/tx_szleitlinien/003-001l_S3_VTE-Prophylaxe_2015-12.pdf.
Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2020; 382(20):1883–93. DOI: 10.1056/NEJMoa1915928. http://www.ncbi.nlm.nih.gov/pubmed/32222134.
Arundel C, Lam PH, Khosla R, et al. Association of 30-Day All-Cause Readmission with Long-Term Outcomes in Hospitalized Older Medicare Beneficiaries with Heart Failure. Am J Med 2016; 129(11):1178–84. DOI: 10.1016/j.amjmed.2016.06.018. http://www.ncbi.nlm.nih.gov/pubmed/27401949.
Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Hydrochlorothiazid - Risiko von nichtmelanozytärem Hautkrebs [Basalzellkarzinom (Basaliom); Plattenepithelkarzinom der Haut (Spinaliom)]. Rote-Hand-Brief vom 17.Oktober 2018. 2018 [cited: 2023-09-07]. https://www.akdae.de/fileadmin/user_upload/akdae/Arzneimittelsicherheit/RHB/Archiv/2018/20181017.pdf.
Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ). Verschärfte Empfehlungen bezüglich des Risikos schwerer Überempfindlichkeitsreaktionen auf Eisen-Präparate zur intravenösen Applikation. 2013 (Rote-Hand-Briefe 2013) [cited: 2018-10-09]. http://www.akdae.de/Arzneimittelsicherheit/RHB/Archiv/2013/20131021.pdf.
Arzt M, Woehrle H, Oldenburg O, et al. Prevalence and Predictors of Sleep-Disordered Breathing in Patients With Stable Chronic Heart Failure: The SchlaHF Registry. JACC Heart Fail 2016; 4(2):116–25. DOI: 10.1016/j.jchf.2015.09.014. http://www.ncbi.nlm.nih.gov/pubmed/26682790.
Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006. Z Arztl Fortbild Qualitatssich 2005; 99(8):468–519.
Ascoeta MS, Marijon E, Defaye P, et al. Impact of early complications on outcomes in patients with implantable cardioverter-defibrillator for primary prevention. Heart Rhythm 2016; 13(5):1045–51. DOI: 10.1016/j.hrthm.2015.12.046. http://www.ncbi.nlm.nih.gov/pubmed/26749313.
Ashworth DC, Maule SP, Stewart F, et al. Setting and techniques for monitoring blood pressure during pregnancy. Cochrane Database Syst Rev 2020; 8(8):CD012739. DOI: 10.1002/14651858.CD012739.pub2. http://www.ncbi.nlm.nih.gov/pubmed/32748394.
Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328(7454):1490–7. http://www.ncbi.nlm.nih.gov/pubmed/15205295.
Auerbach AD, Hamel MB, Davis RB, et al. Resource use and survival of patients hospitalized with congestive heart failure: Differences in care by specialty of the attending physician. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 2000; 132(3):191–200. http://www.ncbi.nlm.nih.gov/pubmed/10651599.
Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clin Proc 2015; 90(1):12–23. DOI: 10.1016/j.mayocp.2014.10.007. http://www.ncbi.nlm.nih.gov/pubmed/25572192.
Aziz S, Leon AR, El-Chami MF. The subcutaneous defibrillator: A review of the literature. J Am Coll Cardiol 2014; 63(15):1473–9. DOI: 10.1016/j.jacc.2014.01.018. http://www.ncbi.nlm.nih.gov/pubmed/24530663.
Baker DW, Hayes RP, Massie BM, et al. Variations in family physicians‘ and cardiologists‘ care for patients with heart failure. Am Heart J 1999; 138(5 Pt 1):826–34. http://www.ncbi.nlm.nih.gov/pubmed/10539812.
Balion C, Don-Wauchope A, Hill S, et al. Use of Natriuretic Peptide Measurement in the Management of Heart Failure. 2013 (Comparative Effectiveness Review; 126) [cited: 2018-10-10]. http://effectivehealthcare.ahrq.gov/sites/default/files/pdf/heart-failure-natriuretic-peptide_research.pdf.
Ballout A, Goffin E, Yombi JC, et al. Vaccinations for adult solid organ transplant recipient: Current recommendations. Transplant. Proc 2005; 37(6):2826–7. http://www.ncbi.nlm.nih.gov/pubmed/16182821.
Bandelow B, Wiltink J, Alpers GW, et al. S3-Leitlinie Behandlung von Angststörungen. 2014 [cited: 2019-10-02]. https://www.awmf.org/uploads/tx_szleitlinien/051-028l_S3_Angstst%C3%B6rungen_2014-05-abgelaufen.pdf.
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J Med 2005; 352(3):225–37. http://www.ncbi.nlm.nih.gov/pubmed/15659722.
Bardy GH, Smith WM, Hood MA, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010; 363(1):36–44. DOI: 10.1056/NEJMoa0909545. http://www.ncbi.nlm.nih.gov/pubmed/20463331.
Barents M, van der Horst IC, Voors AA, et al. Prevalence and misdiagnosis of chronic heart failure in nursing home residents: The role of B-type natriuretic peptides. Neth. Heart J 2008; 16(4):123–8. http://www.ncbi.nlm.nih.gov/pubmed/18427636.
Barlow J, Wright C, Sheasby J, et al. Self-management approaches for people with chronic conditions: A review. Patient Educ Couns. 2002; 48(2):177–87. http://www.ncbi.nlm.nih.gov/pubmed/12401421.
Barra S, Providencia R, Tang A, et al. Importance of Implantable Cardioverter-Defibrillator Back-Up in Cardiac Resynchronization Therapy Recipients: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2015; 4(11):e002539. DOI: 10.1161/JAHA.115.002539. http://www.ncbi.nlm.nih.gov/pubmed/26546574.
Barry VW, Baruth M, Beets MW, et al. Fitness vs. fatness on all-cause mortality: A meta-analysis. Prog Cardiovasc Dis 2014; 56(4):382–90. DOI: 10.1016/j.pcad.2013.09.002. http://www.ncbi.nlm.nih.gov/pubmed/24438729.
Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e691S-e736S. DOI: 10.1378/chest.11-2300. http://www.ncbi.nlm.nih.gov/pubmed/22315276.
Bauersachs J, Maier L, ter Horst N, et al. Lieferengpass Digitoxin. Kardiologie 2023; 17(1):39–42. DOI: 10.1007/s12181-022-00585-x.
Bavendiek U, Aguirre DL, Koch A, et al. Assumption versus evidence: The case of digoxin in atrial fibrillation and heart failure. Eur Heart J 2017(0):1–5. DOI: 10.1093/eurheartj/ehw577. http://www.ncbi.nlm.nih.gov/pubmed/28065909.
Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: Clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987; 57(1):17–22. DOI: 10.1136/hrt.57.1.17. http://www.ncbi.nlm.nih.gov/pubmed/3541995.
Bein T, Bischoff M, Brückner U, et al. Lagerungstherapie und Frühmobilisation zur Prophylaxe oder Therapie von pulmonalen Funktionsstörungen. S2e-Leitlinie. 2015 [cited: 2018-04-20]. http://www.awmf.org/uploads/tx_szleitlinien/001-015l_S2e_Lagerungstherapie_Fr%C3%BChmobilisation_pulmonale_Funktionsst%C3%B6rungen_2015-05.pdf.
Benstoem C, Kalvelage C, Breuer T, et al. Ivabradine as adjuvant treatment for chronic heart failure. Cochrane Database Syst Rev 2020; 11(11):CD013004. DOI: 10.1002/14651858.CD013004.pub2. http://www.ncbi.nlm.nih.gov/pubmed/33147368.
Berg DD, Jhund PS, Docherty KF, et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol 2021; 6(5):499–507. DOI: 10.1001/jamacardio.2020.7585. http://www.ncbi.nlm.nih.gov/pubmed/33595593.
Betts TR, Sadarmin PP, Tomlinson DR, et al. Absolute risk reduction in total mortality with implantable cardioverter defibrillators: Analysis of primary and secondary prevention trial data to aid risk/benefit analysis. Europace 2013; 15(6):813–9. DOI: 10.1093/europace/eus427. http://www.ncbi.nlm.nih.gov/pubmed/23365069.
Birnie DH, Ha A, Higginson L, et al. Impact of QRS morphology and duration on outcomes after cardiac resynchronization therapy: Results from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT). Circ Heart Fail 2013; 6(6):1190–8. DOI: 10.1161/CIRCHEARTFAILURE.113.000380. http://www.ncbi.nlm.nih.gov/pubmed/23995437.
Bjarnason-Weherns B, Held K, Hoberg E, et al. Deutsche Leitlinie zur Rehabilitation von Patienten mit Herz-Kreislauferkrankungen (DLL-KardReha). Clin Res Cardiol. Suppl 2007; 2(3):1–54.
Blanc JJ. Biopace Trial Preliminary Results. ESC Congress 2014: Presentation. 2014 [cited: 2023-09-07]. https://dokumen.tips/documents/biopace-trial-preliminary-results-2014blancbiopacepdf-biopace-trial-preliminary.html?page=1.
Blessberger H, Kammler J, Domanovits H, et al. Perioperative beta-blockers for preventing surgery-related mortality and morbidity. Cochrane Database Syst Rev 2018; 3(3):CD004476. DOI: 10.1002/14651858.CD004476.pub3. http://www.ncbi.nlm.nih.gov/pubmed/29533470.
Bock R de, van den Noortgate N, Piers R. Validation of the Supportive and Palliative Care Indicators Tool in a Geriatric Population. J Palliat Med 2018; 21(2):220–4. DOI: 10.1089/jpm.2017.0205. http://www.ncbi.nlm.nih.gov/pubmed/28792787.
Bogale N, Priori S, Gitt A, et al. The European cardiac resynchronization therapy survey: Patient selection and implantation practice vary according to centre volume. Europace 2011; 13(10):1445–53. DOI: 10.1093/europace/eur173. http://www.ncbi.nlm.nih.gov/pubmed/21712274.
Bohm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: Analysis from the SHIFT study. Clin Res Cardiol 2013; 102(1):11–22. DOI: 10.1007/s00392-012-0467-8. http://www.ncbi.nlm.nih.gov/pubmed/22575988.
Böhm M, Drexler H, Oswald H, et al. Fluid status telemedicine alerts for heart failure: A randomized controlled trial. Eur Heart J 2016; 37(41):3154–63. DOI: 10.1093/eurheartj/ehw099. http://www.ncbi.nlm.nih.gov/pubmed/26984864.
Böhm M, Pogue J, Kindermann I, et al. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. Eur J Heart Fail 2014; 16(3):325–33. DOI: 10.1002/ejhf.23. http://www.ncbi.nlm.nih.gov/pubmed/24464788.
Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372(12):1114–25. DOI: 10.1056/NEJMoa1408544. http://www.ncbi.nlm.nih.gov/pubmed/25785969.
Borggrefe MM, Lawo T, Butter C, et al. Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J 2008; 29(8):1019–28. DOI: 10.1093/eurheartj/ehn020. http://www.ncbi.nlm.nih.gov/pubmed/18270213.
Boveda S, Lenarczyk R, Haugaa K, et al. Implantation of subcutaneous implantable cardioverter defibrillators in Europe: Results of the European Heart Rhythm Association survey. Europace 2016; 18(9):1434–9. DOI: 10.1093/europace/euw258. http://www.ncbi.nlm.nih.gov/pubmed/27582309.
Boxer RS, Dolansky MA, Frantz MA, et al. The Bridge Project: Improving heart failure care in skilled nursing facilities. J Am Med Dir Assoc 2012; 13(1):83–7. DOI: 10.1016/j.jamda.2011.01.005. http://www.ncbi.nlm.nih.gov/pubmed/21450244.
Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016; 134(23):e535-e578. DOI: 10.1161/CIR.0000000000000450. http://www.ncbi.nlm.nih.gov/pubmed/27799274.
Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 2003; 42(7):1226–33. http://www.ncbi.nlm.nih.gov/pubmed/14522486.
Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 2013; 34(29):2281–329. DOI: 10.1093/eurheartj/eht150. http://www.ncbi.nlm.nih.gov/pubmed/23801822.
Brignole M, Botto G, Mont L, et al. Cardiac resynchronization therapy in patients undergoing atrioventricular junction ablation for permanent atrial fibrillation: A randomized trial. Eur Heart J 2011; 32(19):2420–9. DOI: 10.1093/eurheartj/ehr162. http://www.ncbi.nlm.nih.gov/pubmed/21606084.
Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J Med 2004; 350(21):2140–50. http://www.ncbi.nlm.nih.gov/pubmed/15152059.
Brozena SC, Jessup M. The new staging system for heart failure. What every primary care physician should know. Geriatrics 2003; 58(6):31–6. http://www.ncbi.nlm.nih.gov/pubmed/12813870.
Brush S, Budge D, Alharethi R, et al. End-of-life decision making and implementation in recipients of a destination left ventricular assist device. J Heart Lung Transplant 2010; 29(12):1337–41. DOI: 10.1016/j.healun.2010.07.001. http://www.ncbi.nlm.nih.gov/pubmed/20817564.
Bryant-Lukosius D, Carter N, Reid K, et al. The clinical effectiveness and cost-effectiveness of clinical nurse specialist-led hospital to home transitional care: A systematic review. J Eval Clin Pract 2015; 21(5):763–81. DOI: 10.1111/jep.12401. http://www.ncbi.nlm.nih.gov/pubmed/26135524.
Buckberg GD. Defining the relationship between akinesia and dyskinesia and the cause of left ventricular failure after anterior infarction and reversal of remodeling to restoration. J Thorac Cardiovasc Surg 1998; 116(1):47–9. http://www.ncbi.nlm.nih.gov/pubmed/9671896.
Bullinger M, Kirchberger I. SF-36. Fragebogen zum Gesundheitszustand. Handanweisung. Göttingen: Hogrefe; 1998.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz – Leitlinienreport, 3. Auflage. Version 3. 2021 [cited: 2020-09-22]. DOI: 10.6101/AZQ/000483. http://doi.org/10.6101/AZQ/000483.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Programm für Nationale VersorgungsLeitlinien - Methodenreport, 5. Auflage. Version 1. 2017 [cited: 2019-09-05]. DOI: 10.6101/AZQ/000169. http://doi.org/10.6101/AZQ/000169.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz – Leitlinienreport. Version 4.0. 2023 [cited: 2023-11-01]. DOI: 10.6101/AZQ/000509. http://doi.org/10.6101/AZQ/000509.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK – Langfassung, 5. Auflage. Version 1. 2019 [cited: 2019-04-11]. DOI: 10.6101/AZQ/000419. http://doi.org/10.6101/AZQ/000419.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Langfassung, 1. Auflage. Version 7. 2009 [cited: 2017-09-20]. DOI: 10.6101/AZQ/000166. http://doi.org/10.6101/AZQ/000166.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Langfassung, Version 3.0. 2023 [cited: 2023-04-21]. DOI: 10.6101/AZQ/000503. https://doi.org/10.6101/AZQ/000503.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK – Leitlinienreport, Version 6.0. 2022 [cited: 2022-09-14]. DOI: 10.6101/AZQ/000490. http://doi.org/10.6101/AZQ/000490.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Hypertonie - Langfassung. Version 1.0. 2023 [cited: 2023-06-29]. DOI: 10.6101/AZQ/000502. http://doi.org/10.6101/AZQ/000502.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Teilpublikation der Langfassung, 2. Auflage. Version 1. 2021 [cited: 2021-03-25]. DOI: 10.6101/AZQ/000475. http://doi.org/10.6101/AZQ/000475.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische KHK - Langfassung, 4. Auflage. Version 1. 2016 [cited: 2023-09-07]. DOI: 10.6101/AZQ/000267. https://www.leitlinien.de/themen/khk/archiv/pdf/khk-4aufl-vers1-lang-2.pdf.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Leitlinienreport, 2. Auflage. Version 3. 2017 [cited: 2018-04-23]. DOI: 10.6101/AZQ/000408. http://doi.org/10.6101/AZQ/000408.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma - Langfassung, 2. Auflage. Version 5. 2009 [cited: 2023-09-07]. DOI: 10.6101/AZQ/000163. https://www.leitlinien.de/themen/asthma/archiv/pdf/asthma-2aufl-vers5-lang.pdf.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Leitlinienreport, 2. Auflage. Version 2. 2017 [cited: 2017-09-20]. DOI: 10.6101/AZQ/000391. http://doi.org/10.6101/AZQ/000391.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Asthma - Langfassung, 3. Auflage. Version 1. 2018 [cited: 2018-09-21]. DOI: 10.6101/AZQ/000400. http://doi.org/10.6101/AZQ/000400.
Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV). Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Dtsch Arztebl 1997; 94(33):A-2154-5.
Bundesärztekammer (BÄK). (Muster-)Kursbuch Psychosomatische Grundversorgung mit integriertem Fortbildungscurriculum „Patientenzentrierte Kommunikation“. 2018 [cited: 2023-09-07]. https://www.bundesaerztekammer.de/fileadmin/user_upload/BAEK/Themen/Aus-Fort-Weiterbildung/Weiterbildung/Kursbuecher/2018/MKB_Psychosomatische_GV.pdf.
Bundesgerichtshof (BGH). BGH, Urteil vom 25. Juni 2010 - 2 StR 454/09 - LG Fulda. 2010 [cited: 2017-02-24]. http://juris.bundesgerichtshof.de/cgi-bin/rechtsprechung/document.py?Gericht=bgh&Art=en&sid=59e71abacc0d791b04c31d71800b71af&nr=52999&pos=1&anz=2&Blank=1.pdf.
Bundesministerium der Justiz und für Verbraucherschutz (BMJV). § 630e Aufklärungspflichten. In: Bundesministerium der Justiz und für Verbraucherschutz (BMJV), editor. Bürgerliches Gesetzbuch (BGB); 2017.
Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-Year Results From a Pooled Analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 2015; 65(16):1605–15. DOI: 10.1016/j.jacc.2015.02.047. http://www.ncbi.nlm.nih.gov/pubmed/25908064.
Butt JH, Jhund PS, Belohlávek J, et al. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation 2022; 146(16):1210–24. DOI: 10.1161/CIRCULATIONAHA.122.061754. http://www.ncbi.nlm.nih.gov/pubmed/36029465.
Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341(25):1882–90. DOI: 10.1056/NEJM199912163412503. http://www.ncbi.nlm.nih.gov/pubmed/10601507.
Cammarano C, Silva M, Comee M, et al. Meta-analysis of Ivabradine in Patients With Stable Coronary Artery Disease With and Without Left Ventricular Dysfunction. Clin Ther 2016; 38(2):387–95. DOI: 10.1016/j.clinthera.2015.12.018. http://www.ncbi.nlm.nih.gov/pubmed/26839043.
Carlsson J, Paul NW, Dann M, et al. The deactivation of implantable cardioverter-defibrillators: Medical, ethical, practical, and legal considerations. Dtsch Arztebl Int 2012; 109(33-34):535–41. DOI: 10.3238/arztebl.2012.0535. http://www.ncbi.nlm.nih.gov/pubmed/23152737.
Casimir YE, Williams MM, Liang MY, et al. The effectiveness of patient-centered self-care education for adults with heart failure on knowledge, self-care behaviors, quality of life, and readmissions: A systematic review. JBI Database System Rev Implement Rep 2014(2):188–262. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0068692.
Castro-Gutierrez V, Rada G. Should sodium intake be restricted in chronic heart failure? Medwave. 2016; 16(5 Suppl):e6696. http://www.ncbi.nlm.nih.gov/pubmed/27922584.
Cazeau S, Leclercq C, Lavergne T, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 2001; 344(12):873–80. http://www.ncbi.nlm.nih.gov/pubmed/11259720.
Chan E, Giallauria F, Vigorito C, et al. Exercise training in heart failure patients with preserved ejection fraction: A systematic review and meta-analysis. Monaldi Arch Chest Dis 2016; 86(1-2):759. DOI: 10.4081/monaldi.2016.759. http://www.ncbi.nlm.nih.gov/pubmed/27748473.
Chang KY, Giorgio K, Schmitz K, et al. Effect of Chronic Digoxin Use on Mortality and Heart Failure Hospitalization in Pulmonary Arterial Hypertension. J Am Heart Assoc 2023; 12(6):e027559. DOI: 10.1093/eurheartj/ehz395. http://www.ncbi.nlm.nih.gov/pubmed/36892094.
Charaya K, Shchekochikhin D, Andreev D, et al. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: A pilot study. Open Heart 2022; 9(1). DOI: 10.1002/ejhf.2249. http://www.ncbi.nlm.nih.gov/pubmed/35609943.
Chen BW, Liu Q, Wang X, et al. Are dual-chamber implantable cardioverter-defibrillators really better than single-chamber ones? A systematic review and meta-analysis. J Interv Card Electrophysiol. 2014; 39(3):273–80. DOI: 10.1007/s10840-014-9873-3. http://www.ncbi.nlm.nih.gov/pubmed/24532113.
Chen CY, Stevenson LW, Stewart GC, et al. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: Cohort study of older patients with heart failure. BMJ 2015; 351:h3529. http://www.ncbi.nlm.nih.gov/pubmed/26174233.
Chen J, Ross JS, Carlson MD, et al. Skilled nursing facility referral and hospital readmission rates after heart failure or myocardial infarction. Am J Med 2012; 125(1):100–9. DOI: 10.1016/j.amjmed.2011.06.011. http://www.ncbi.nlm.nih.gov/pubmed/22195535.
Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch. Intern. Med 2011; 171(6):550–6. DOI: 10.1001/archinternmed.2011.31. http://www.ncbi.nlm.nih.gov/pubmed/21444844.
Chin MH, Friedmann PD, Cassel CK, et al. Differences in generalist and specialist physicians‘ knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen. Intern Med 1997; 12(9):523–30. http://www.ncbi.nlm.nih.gov/pubmed/9294785.
CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999; 353(9146):9–13. http://www.ncbi.nlm.nih.gov/pubmed/10023943.
Cleland JG, Abraham WT, Linde C, et al. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013; 34(46):3547–56. DOI: 10.1093/eurheartj/eht290. http://www.ncbi.nlm.nih.gov/pubmed/23900696.
Cleland JG, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: An individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018; 39(1):26–35. DOI: 10.1093/eurheartj/ehx564. http://www.ncbi.nlm.nih.gov/pubmed/29040525.
Cleland JG, Calvert MJ, Verboven Y, et al. Effects of cardiac resynchronization therapy on long-term quality of life: An analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J 2009; 157(3):457–66. DOI: 10.1016/j.ahj.2008.11.006. http://www.ncbi.nlm.nih.gov/pubmed/19249415.
Cleland JG, Daubert JC, Erdmann E, et al. Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]. Eur Heart J 2006; 27(16):1928–32. DOI: 10.1093/eurheartj/ehl099. http://www.ncbi.nlm.nih.gov/pubmed/16782715.
Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J Med 2005; 352(15):1539–49. http://www.ncbi.nlm.nih.gov/pubmed/15753115.
Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators. Eur Heart J 1997; 18(1):41–51. http://www.ncbi.nlm.nih.gov/pubmed/9049514.
Cleland JG, Freemantle N, Erdmann E, et al. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial. Eur J Heart Fail 2012; 14(6):628–34. DOI: 10.1093/eurjhf/hfs055. http://www.ncbi.nlm.nih.gov/pubmed/22552183.
Cleland JG, Louis AA, Rigby AS, et al. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: The Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol 2005; 45(10):1654–64. http://www.ncbi.nlm.nih.gov/pubmed/15893183.
Cleland JG, Mareev Y, Linde C. Reflections on EchoCRT: Sound guidance on QRS duration and morphology for CRT? Eur Heart J 2015; 36(30):1948–51. DOI: 10.1093/eurheartj/ehv264. http://www.ncbi.nlm.nih.gov/pubmed/26180135.
Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27(19):2338–45. http://www.ncbi.nlm.nih.gov/pubmed/16963472.
Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345(23):1667–75. http://www.ncbi.nlm.nih.gov/pubmed/11759645.
Colucci WS, Kolias TJ, Adams KF, et al. Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 2007; 116(1):49–56. DOI: 10.1161/CIRCULATIONAHA.106.666016. http://www.ncbi.nlm.nih.gov/pubmed/17576868.
Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000; 101(11):1297–302. http://www.ncbi.nlm.nih.gov/pubmed/10725290.
Connolly SJ, Hallstrom AP, Cappato R, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg Canadian Implantable Defibrillator Study. Eur Heart J 2000; 21(24):2071–8. http://www.ncbi.nlm.nih.gov/pubmed/11102258.
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316(23):1429–35. http://www.ncbi.nlm.nih.gov/pubmed/2883575.
Cornelis J, Beckers P, Taeymans J, et al. Comparing exercise training modalities in heart failure: A systematic review and meta-analysis. Int J Cardiol 2016; 221:867–76. DOI: 10.1016/j.ijcard.2016.07.105. http://www.ncbi.nlm.nih.gov/pubmed/27434363.
Cosmi F, Di Giulio P, Masson S, et al. Regular wine consumption in chronic heart failure: Impact on outcomes, quality of life, and circulating biomarkers. Circ Heart Fail 2015; 8(3):428–37. DOI: 10.1161/CIRCHEARTFAILURE.114.002091. http://www.ncbi.nlm.nih.gov/pubmed/25925415.
Cowie MR. Ivabradine and atrial fibrillation: What should we tell our patients? Heart 2014; 100(19):1487–8. DOI: 10.1136/heartjnl-2014-306287. http://www.ncbi.nlm.nih.gov/pubmed/24986893.
Curtis AB, Worley SJ, Adamson PB, et al. Biventricular pacing for atrioventricular block and systolic dysfunction. N Engl J Med 2013; 368(17):1585–93. DOI: 10.1056/NEJMoa1210356. http://www.ncbi.nlm.nih.gov/pubmed/23614585.
Daamen MA, Hamers JP, Gorgels AP, et al. Heart failure in nursing home residents; a cross-sectional study to determine the prevalence and clinical characteristics. BMC Geriatr 2015; 15:167. DOI: 10.1186/s12877-015-0166-1. http://www.ncbi.nlm.nih.gov/pubmed/26675117.
Dahrmann B, Sindermann J, Geldmacher T, et al. Lebensqualität und psychisches Befinden von Patienten mit schwerer Herzinsuffizienz mit und ohne apparative Unterstützung der Funktion des linken Ventrikels – eine Querschnittsstudie. Z Psychosom. Med Psychother. 2017; 63(4):388–404. DOI: 10.13109/zptm.2017.63.4.388. http://www.ncbi.nlm.nih.gov/pubmed/29214945.
Damman K, Beusekamp JC, Boorsma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). Eur J Heart Fail 2020; 22(4):713–22. DOI: 10.1002/ejhf.1713. http://www.ncbi.nlm.nih.gov/pubmed/31912605.
Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial. Lancet 2001; 357(9266):1385–90. http://www.ncbi.nlm.nih.gov/pubmed/11356434.
Daubert C, Gold MR, Abraham WT, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: Insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009; 54(20):1837–46. DOI: 10.1016/j.jacc.2009.08.011. http://www.ncbi.nlm.nih.gov/pubmed/19800193.
Deichl A, Wachter R, Edelmann F. Komorbiditäten bei Herzinsuffizienz mit erhaltener Ejektionsfraktion. Herz 2022; 47(4):301–7. DOI: 10.1007/s00059-022-05123-9. http://www.ncbi.nlm.nih.gov/pubmed/35674774.
Dempsey JT, Matta LS, Carter DM, et al. Assessment of Drug Therapy-Related Issues in an Outpatient Heart Failure Population and the Potential Impact of Pharmacist-Driven Intervention. J Pharm Pract 2016; 30(3):318–23. DOI: 10.1177/0897190016641491. http://www.ncbi.nlm.nih.gov/pubmed/27080398.
Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015; 36(30):1990–7. DOI: 10.1093/eurheartj/ehv186. http://www.ncbi.nlm.nih.gov/pubmed/26022006.
Deutsche Gesellschaft für Ernährung, Österreichische Gesellschaft für Ernährung, Schweizerische Gesellschaft für Ernährungsforschung. D-A-CH-Referenzwerte für die Nährstoffzufuhr. 2. Aufl. ed. Neustadt/Weinstraße: Neuer Umschau Buchverl.; 2015.
Deutsche Gesellschaft für Prävention und Rehabilitationvon Herz-Kreislauferkrankungen (DGPR), Bjarnason-Weherns B. Leitlinie körperliche Aktivität zur Sekundärprävention und Therapie kardiovaskulärer Erkrankungen. Clin Res Cardiol. Suppl 2009; 4(4 Suppl):1–44. DOI: 10.1007/s11789-009-0078-8.
Deutsche Gesellschaft für Psychiatrie und Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN), Deutsche Gesellschaft für Neurologie (DGN), Deutsche Alzheimer Gesellschaft – Selbsthilfe Demenz. S3-Leitlinie Demenzen: Registernummer 038-013. Version 2016-07. 2016 [cited: 2018-02-06]. https://www.awmf.org/leitlinien/detail/ll/038-013.html.
Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN), Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), et al. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression - Langfassung, 2. Auflage. Version 5. 2015 [cited: 2018-06-06]. DOI: 10.6101/AZQ/000364. http://doi.org/10.6101/AZQ/000364.
Deutsche Gesellschaft für Schlafforschung und Schlafmedizin (DGSM). S3 Leitlinie Nicht erholsamer Schlaf/Schlafstörung Kapitel „Schlafbezogene Atmungsstörungen bei Erwachsenen“ Version 2.0. S3-Leitlinie. 2017 [cited: 2018-11-09].
Deutsche Herzstiftung. Deutscher Herzbericht 2015. 27. Sektorenübergreifende Versorgungsanalyse zur Kardiologie und Herzchirurgie in Deutschland. Frankfurt/Main: Deutsche Herzstiftung; 2015.
Deutsche Herzstiftung. Deutscher Herzbericht 2016. 28. Sektorenübergreifende Versorgungsanalyse zur Kardiologie und Herzchirurgie in Deutschland. Frankfurt/Main: Deutsche Herzstiftung; 2016.
Deutsche Rentenversicherung Bund (DRV-Bund). Curriculum Herzinsuffizienz. Standardisierte Patientenschulung. 2015 [cited: 2018-05-24]. https://www.deutsche-rentenversicherung.de/SharedDocs/Downloads/DE/Experten/infos_reha_einrichtungen/gesundheitstraining/kardiologie_herzinsuffizienz.html.
Deutschsprachige Gesellschaft für Psychotraumatologie (DeGPT), Deutsche Gesellschaft für Psychotherapeutische Medizin und ärztliche Psychotherapie (DGPM), Deutsches Kollegium für Psychosomatische Medizin (DKPM), et al. S3-Leitlinie. Posttraumatische Belastungsstörung. ICD 10: F 43.1. 2011 [cited: 2019-03-07]. https://www.awmf.org/uploads/tx_szleitlinien/051-010l_S3_Posttraumatische_Belastungsstoerung_2012-abgelaufen.pdf.
Dickstein K, Bogale N, Priori S, et al. The European cardiac resynchronization therapy survey. Eur Heart J 2009; 30(20):2450–60. DOI: 10.1093/eurheartj/ehp359. http://www.ncbi.nlm.nih.gov/pubmed/19723694.
Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29(19):2388–442. http://www.ncbi.nlm.nih.gov/pubmed/18799522.
Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360(9335):752–60. http://www.ncbi.nlm.nih.gov/pubmed/12241832.
Dieberg G, Ismail H, Giallauria F, et al. Clinical outcomes and cardiovascular responses to exercise training in heart failure patients with preserved ejection fraction: A systematic review and meta-analysis. J Appl Physiol (1985) 2015; 119(6):726–33. DOI: 10.1152/japplphysiol.00904.2014. http://www.ncbi.nlm.nih.gov/pubmed/25749444.
Docherty KF, Campbell RT, Brooksbank KJ, et al. Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation 2021; 144(3):199–209. DOI: 10.1161/CIRCULATIONAHA.121.054892. http://www.ncbi.nlm.nih.gov/pubmed/33983794.
Dor V, Sabatier M, Di Donato M, et al. Efficacy of endoventricular patch plasty in large postinfarction akinetic scar and severe left ventricular dysfunction: Comparison with a series of large dyskinetic scars. J Thorac Cardiovasc Surg 1998; 116(1):50–9. http://www.ncbi.nlm.nih.gov/pubmed/9671897.
Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol. 2005; 16(11):1160–5. http://www.ncbi.nlm.nih.gov/pubmed/16302897.
Doughty RN, Whalley GA, Walsh HA, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN Echo Substudy. Circulation 2004; 109(2):201–6. DOI: 10.1161/01.CIR.0000108928.25690.94. http://www.ncbi.nlm.nih.gov/pubmed/14707020.
Doukky R, Mangla A, Ibrahim Z, et al. Impact of Physical Inactivity on Mortality in Patients With Heart Failure. Am J Cardiol 2016; 117(7):1135–43. DOI: 10.1016/j.amjcard.2015.12.060. http://www.ncbi.nlm.nih.gov/pubmed/26853954.
Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35(3):681–9. http://www.ncbi.nlm.nih.gov/pubmed/10716471.
Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 32(3):695–703. DOI: 10.1016/s0735-1097(98)00297-6. http://www.ncbi.nlm.nih.gov/pubmed/9741514.
Dries DL, Strong MH, Cooper RS, et al. Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. J Am Coll Cardiol 2002; 40(2):311–7. DOI: 10.1016/s0735-1097(02)01943-5. http://www.ncbi.nlm.nih.gov/pubmed/12106937.
Driscoll A, Currey J, Tonkin A, et al. Nurse-led titration of angiotensin converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction. Cochrane Database Syst Rev 2015; 12:CD009889. DOI: 10.1002/14651858.CD009889.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26689943.
Echouffo-Tcheugui JB, Erqou S, Butler J, et al. Assessing the Risk of Progression From Asymptomatic Left Ventricular Dysfunction to Overt Heart Failure: A Systematic Overview and Meta-Analysis. JACC Heart Fail 2016; 4(4):237–48. DOI: 10.1016/j.jchf.2015.09.015. http://www.ncbi.nlm.nih.gov/pubmed/26682794.
Edelmann F, Gelbrich G, Düngen H-D, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: Results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011; 58(17):1780–91. DOI: 10.1016/j.jacc.2011.06.054. http://www.ncbi.nlm.nih.gov/pubmed/21996391.
Edep ME, Shah NB, Tateo IM, et al. Differences between primary care physicians and cardiologists in management of congestive heart failure: Relation to practice guidelines. J Am Coll Cardiol 1997; 30(2):518–26. http://www.ncbi.nlm.nih.gov/pubmed/9247527.
Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344(22):1659–67. http://www.ncbi.nlm.nih.gov/pubmed/11386264.
Eid PS, Ibrahim DA, Zayan AH, et al. Comparative effects of furosemide and other diuretics in the treatment of heart failure: A systematic review and combined meta-analysis of randomized controlled trials. Heart Fail Rev 2021; 26(1):127–36. DOI: 10.1007/s10741-020-10003-7. http://www.ncbi.nlm.nih.gov/pubmed/32783109.
Ekman I, Fagerberg B, Skoog I. The clinical implications of cognitive impairment in elderly patients with chronic heart failure. J Cardiovasc Nurs 2001; 16(1):47–55. http://www.ncbi.nlm.nih.gov/pubmed/11587240.
El Hadidi S, Rosano G, Tamargo J, et al. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. Eur Heart J Cardiovasc Pharmacother 2022; 8(2):187–210. DOI: 10.1093/ehjcvp/pvaa108. http://www.ncbi.nlm.nih.gov/pubmed/32941594.
Ellingsen O, Halle M, Conraads V, et al. High-Intensity Interval Training in Patients With Heart Failure With Reduced Ejection Fraction. Circulation 2017; 135(9):839–49. DOI: 10.1161/CIRCULATIONAHA.116.022924. http://www.ncbi.nlm.nih.gov/pubmed/28082387.
Ellis G, Gardner M, Tsiachristas A, et al. Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev 2017; 9:CD006211. DOI: 10.1002/14651858.CD006211.pub3. http://www.ncbi.nlm.nih.gov/pubmed/28898390.
Emami A, Saitoh M, Valentova M, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: Results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur J Heart Fail 2018; 20(11):1580–7. DOI: 10.1002/ejhf.1304. http://www.ncbi.nlm.nih.gov/pubmed/30160804.
Erdmann E, Lechat P, Verkenne P, et al. Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001; 3(4):469–79. http://www.ncbi.nlm.nih.gov/pubmed/11511434.
Erkapic D, Sperzel J, Stiller S, et al. Long-term benefit of implantable cardioverter/defibrillator therapy after elective device replacement: Results of the INcidence free SUrvival after ICD REplacement (INSURE) trial—a prospective multicentre study. Eur Heart J 2013; 34(2):130–7. DOI: 10.1093/eurheartj/ehs177. http://www.ncbi.nlm.nih.gov/pubmed/22771679.
Ettinger S, Stanak M, Huic M, et al. Tragbare Kardioverter Defibrillator Therapie zur Primär- und Sekundärprävention von plötzlichem Herzstillstand Deutsche Zusammenfassung des EUnetHTA-Berichts. 2016 (Decision Support Document; 103) [cited: 2017-07-17]. http://eprints.hta.lbg.ac.at/1109/1/DSD_103.pdf.
Europarat, Verbindung der Schweizer Ärztinnen und Ärzte, Ärztliche Zentralstelle Qualitätssicherung (ÄZQ), et al. Entwicklung einer Methodik für die Ausarbeitung von Leitlinien für optimale medizinische Praxis. Empfehlung Rec (2001)13 des Europarates am 10. Oktober 2001 und Erläuterndes Memorandum. Deutschsprachige Ausgabe. Z Arztl. Fortbild. Qualitatssich. 2002; 96(Suppl III):3–60.
European Medicines Agency (EMA). Forxiga. dapagliflozin. product information. 17/03/2021 Forxiga - EMEA/H/C/002322 - IG/1335/G. 2021. 2021 [cited: 2021-03-24]. https://www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_de.pdf.
European Medicines Agency (EMA). Jardiance. empagliflozin. product information. 17/06/2021 Jardiance - EMEA/H/C/002677 - II/0055. 2021 [cited: 2021-08-16]. https://www.ema.europa.eu/documents/product-information/jardiance-epar-product-information_de.pdf.
EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3):199–208. http://www.ncbi.nlm.nih.gov/pubmed/10109801.
Evans WJ, Morley JE, Argilés J, et al. Cachexia: A new definition. Clin Nutr 2008; 27(6):793–9. DOI: 10.1016/j.clnu.2008.06.013. http://www.ncbi.nlm.nih.gov/pubmed/18718696.
Exner DV, Dries DL, Waclawiw MA, et al. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999; 33(4):916–23. http://www.ncbi.nlm.nih.gov/pubmed/10091816.
Ezekowitz JA, McMullan CJ, Westerhout CM, et al. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial. Circ Heart Fail 2023; 16(9):e010599. DOI: 10.1161/CIRCHEARTFAILURE.123.010599. http://www.ncbi.nlm.nih.gov/pubmed/37417824.
Ezekowitz JA, O‘Meara E, McDonald MA, et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Can J Cardiol 2017; 33(11):1342–433. DOI: 10.1016/j.cjca.2017.08.022. http://www.ncbi.nlm.nih.gov/pubmed/29111106.
Faller H, Steinbuchel T, Schowalter M, et al. Der Kansas City Cardiomyopathy Questionnaire (KCCQ) - ein neues krankheitsspezifisches Messinstrument zur Erfassung der Lebensqualität bei chronischer Herzinsuffizienz - Psychometrische Prüfung der deutschen Version. Psychother. Psychosom. Med Psychol. 2005; 55(3-4):200–8. http://www.ncbi.nlm.nih.gov/pubmed/15800814.
Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev 2012(2):CD003838. DOI: 10.1002/14651858.CD003838.pub3. http://www.ncbi.nlm.nih.gov/pubmed/22336795.
Farwell D, Patel NR, Hall A, et al. How many people with heart failure are appropriate for biventricular resynchronization? Eur Heart J 2000; 21(15):1246–50. DOI: 10.1053/euhj.1999.1985. http://www.ncbi.nlm.nih.gov/pubmed/10924314.
Feldman AM, Haller JA, DeKosky ST. Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations. JAMA 2016; 315(1):25–6. DOI: 10.1001/jama.2015.17632. http://www.ncbi.nlm.nih.gov/pubmed/26641736.
Feltner C, Jones CD, Cene CW, et al. Transitional care interventions to prevent readmissions for persons with heart failure: A systematic review and meta-analysis. Ann Intern Med 2014; 160(11):774–84. DOI: 10.7326/M14-0083. http://www.ncbi.nlm.nih.gov/pubmed/24862840.
Fergenbaum J, Bermingham S, Krahn M, et al. Care in the Home for the Management of Chronic Heart Failure: Systematic Review and Cost-Effectiveness Analysis. J Cardiovasc Nurs 2015; 30(4 Suppl 1):S44-S51. DOI: 10.1097/JCN.0000000000000235. http://www.ncbi.nlm.nih.gov/pubmed/25658188.
Ferreira JP, Eschalier R, Duarte K, et al. Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial. Circ Heart Fail 2020; 13(5):e006597. DOI: 10.1161/CIRCHEARTFAILURE.119.006597. http://www.ncbi.nlm.nih.gov/pubmed/32354280.
Ferreira JP, Zannad F, Pocock SJ, et al. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. J Am Coll Cardiol 2021; 77(11):1397–407. DOI: 10.1016/j.jacc.2021.01.044. http://www.ncbi.nlm.nih.gov/pubmed/33736821.
Filippatos G, Anker SD, Butler J, et al. Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: A secondary analysis of EMPEROR-Reduced. Eur J Heart Fail 2022; 24(12):2297–304. DOI: 10.1002/ejhf.2707. http://www.ncbi.nlm.nih.gov/pubmed/36194680.
Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26(3):215–25. http://www.ncbi.nlm.nih.gov/pubmed/15642700.
Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355(9215):1575–81. http://www.ncbi.nlm.nih.gov/pubmed/10821360.
Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: A scientific statement from the American Heart Association. Circulation 2013; 128(8):873–934. DOI: 10.1161/CIR.0b013e31829b5b44. http://www.ncbi.nlm.nih.gov/pubmed/23877260.
Flodgren G, Rachas A, Farmer AJ, et al. Interactive telemedicine: Effects on professional practice and health care outcomes. Cochrane Database Syst Rev 2015; 9:CD002098. DOI: 10.1002/14651858.CD002098.pub2. http://www.ncbi.nlm.nih.gov/pubmed/26343551.
Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: Findings from OPTIMIZE-HF. Arch. Intern. Med 2008; 168(8):847–54. DOI: 10.1001/archinte.168.8.847. http://www.ncbi.nlm.nih.gov/pubmed/18443260.
Food and Drug Administration (FDA). Entresto Label and Approval History. 2015 [cited: 2019-10-01]. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/207620Orig1s000ltr.pdf.
Food and Drug Administration (FDA). Entresto. Clinical Pharmacology Review. 2014 [cited: 2018-09-06]. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207620Orig1s000ClinPharmR.pdf.
Forsyth P, Beezer J, Bateman J. Holistic approach to drug therapy in a patient with heart failure. Heart 2023; 109(15):1183-1191. DOI: 10.1136/heartjnl-2022-321764. http://www.ncbi.nlm.nih.gov/pubmed/36898707.
Fox K, Komajda M, Ford I, et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: A pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 2013; 34(29):2263–70. DOI: 10.1093/eurheartj/eht101. http://www.ncbi.nlm.nih.gov/pubmed/23536611.
Freeman JV, Wang Y, Curtis JP, et al. Physician procedure volume and complications of cardioverter-defibrillator implantation. Circulation 2012; 125(1):57–64. DOI: 10.1161/CIRCULATIONAHA.111.046995. http://www.ncbi.nlm.nih.gov/pubmed/22095828.
Freund T, Peters-Klimm F, Boyd CM, et al. Medical Assistant-Based Care Management for High-Risk Patients in Small Primary Care Practices: A Cluster Randomized Clinical Trial. Ann Intern Med 2016; 164(5):323–30. DOI: 10.7326/M14-2403. http://www.ncbi.nlm.nih.gov/pubmed/26833209.
Fried AG, Parker AB, Newton GE, et al. Electrical and hemodynamic correlates of the maximal rate of pressure increase in the human left ventricle. J Card Fail 1999; 5(1):8–16. http://www.ncbi.nlm.nih.gov/pubmed/10194655.
Fromme EK, Stewart TL, Jeppesen M, et al. Adverse experiences with implantable defibrillators in Oregon hospices. Am J Hosp Palliat Care 2011; 28(5):304–9. DOI: 10.1177/1049909110390505. http://www.ncbi.nlm.nih.gov/pubmed/21112878.
Fu M, Pivodic A, Käck O, et al. Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction. Clin Res Cardiol 2023; 112(1):167–74. DOI: 10.1161/CIRCULATIONAHA.119.044586. http://www.ncbi.nlm.nih.gov/pubmed/36443599.
Fuat A, Hungin AP, Murphy JJ. Barriers to accurate diagnosis and effective management of heart failure in primary care: Qualitative study. BMJ 2003; 326(7382):196. http://www.ncbi.nlm.nih.gov/pubmed/12543836.
Funck RC, Blanc JJ, Mueller HH, et al. Biventricular stimulation to prevent cardiac desynchronization: Rationale, design, and endpoints of the ‚Biventricular Pacing for Atrioventricular Block to Prevent Cardiac Desynchronization (BioPace)‘ study. Europace 2006; 8(8):629–35. DOI: 10.1093/europace/eul075. http://www.ncbi.nlm.nih.gov/pubmed/16864616.
Gafford EF, Luckhardt AJ, Swetz KM. Deactivation of a left ventricular assist device at the end of life #269. J Palliat Med 2013; 16(8):980–2. DOI: 10.1089/jpm.2013.9490. http://www.ncbi.nlm.nih.gov/pubmed/23767953.
Gage RM, Burns KV, Bank AJ. Echocardiographic and clinical response to cardiac resynchronization therapy in heart failure patients with and without previous right ventricular pacing. Eur J Heart Fail 2014; 16(11):1199–205. DOI: 10.1002/ejhf.143. http://www.ncbi.nlm.nih.gov/pubmed/25132044.
Galderisi M, Cosyns B, Edvardsen T, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: An expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2017; 18(12):1301–10. DOI: 10.1093/ehjci/jex244. http://www.ncbi.nlm.nih.gov/pubmed/29045589.
Galo J, Celli D, Colombo R. Effect of Sacubitril/Valsartan on Neurocognitive Function: Current Status and Future Directions. Am J Cardiovasc Drugs 2021; 21(3):267–70. DOI: 10.1007/s40256-020-00445-7. http://www.ncbi.nlm.nih.gov/pubmed/33063249.
Gambassi G, Lapane KL, Sgadari A, et al. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. Arch. Intern. Med 2000; 160(1):53–60. http://www.ncbi.nlm.nih.gov/pubmed/10632305.
Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273(18):1450–6. http://www.ncbi.nlm.nih.gov/pubmed/7654275.
Gasparini M, Leclercq C, Lunati M, et al. Cardiac resynchronization therapy in patients with atrial fibrillation: The CERTIFY study (Cardiac Resynchronization Therapy in Atrial Fibrillation Patients Multinational Registry). JACC Heart Fail 2013; 1(6):500–7. DOI: 10.1016/j.jchf.2013.06.003. http://www.ncbi.nlm.nih.gov/pubmed/24622002.
Gastelurrutia P, Benrimoj SI, Espejo J, et al. Negative clinical outcomes associated with drug-related problems in heart failure (HF) outpatients: Impact of a pharmacist in a multidisciplinary HF clinic. J Card Fail 2011; 17(3):217–23. DOI: 10.1016/j.cardfail.2010.10.009. http://www.ncbi.nlm.nih.gov/pubmed/21362530.
Gathright EC, Goldstein CM, Josephson RA, et al. Depression increases the risk of mortality in patients with heart failure: A meta-analysis. J Psychosom Res 2017; 94:82–9. DOI: 10.1016/j.jpsychores.2017.01.010. http://www.ncbi.nlm.nih.gov/pubmed/28183407.
Gemeinsamer Bundesausschuss (G-BA). Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie: Anlage XII – Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V): Vericiguat (chronische Herzinsuffizienz). 2022 [cited: 2023-03-13]. https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/738/#beschluesse.
Gemeinsamer Bundesausschuss (G-BA). Dossier zur Nutzenbewertung gemäβ § 35a SGB V. Sacubitril/Valsartan (Entresto®) Modul 4 A. Erwachsene Patienten mit symptomatischer, chronischer Herzinsuffizienz mit reduzierter Ejektionsfraktion. 2015 [cited: 2019-10-01]. http://www.g-ba.de/downloads/92-975-1312/2015-12-21_Modul4A_Sacubitril-Valsartan.pdf.
Gemeinsamer Bundesausschuss (G-BA). Nutzenbewertungsverfahren zum Wirkstoff Dapagliflozin (Neues Anwendungsgebiet: chronische Herzinsuffizienz mit linksventrikulärer Ejektionsfraktion LVEF > 40 %). 2023 [cited: 2023-08-29]. https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/930/.
Gemeinsamer Bundesausschuss (G-BA). Nutzenbewertungsverfahren zum Wirkstoff Empagliflozin (Neues Anwendungsgebiet: chronische Herzinsuffizienz mit linksventrikulärer Ejektionsfraktion LVEF > 40 %). 2023 [cited: 2023-08-29]. https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/810/.
Gerste B, Günster C. Diagnosehäufigkeit und Inanspruchnahme von Gesundheitsleistungen. In: Klauber J, Günster C, Gerste B, Robra B-P, Schmacke N, editors. Schwerpunkt: Depression. Stuttgart: Schattauer; 2014, p. 257–308.
Gervais R, Leclercq C, Shankar A, et al. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: A sub-analysis of the CARE-HF trial. Eur J Heart Fail 2009; 11(7):699–705. DOI: 10.1093/eurjhf/hfp074. http://www.ncbi.nlm.nih.gov/pubmed/19505883.
Ghali JK, Kadakia S, Cooper R, et al. Precipitating factors leading to decompensation of heart failure. Traits among urban blacks. Arch. Intern. Med 1988; 148(9):2013–6. http://www.ncbi.nlm.nih.gov/pubmed/3046541.
Ghosh RK, Ball S, Prasad V, et al. Depression in heart failure: Intricate relationship, pathophysiology and most updated evidence of interventions from recent clinical studies. Int J Cardiol 2016; 224:170–7. DOI: 10.1016/j.ijcard.2016.09.063. http://www.ncbi.nlm.nih.gov/pubmed/27657469.
Gillespie F, Abraha I, Amicosante AM, et al. Implantable LVAD (Left Ventricular Assist Device) in addition to guideline directed medical therapy (GDMT) in end stage heart failure. HTA Report. 2015 [cited: 2019-10-01]. http://www.salute.gov.it/imgs/C_17_ReportDispositivi_13_documentoInglese_inglese_itemName_0_documentoENG.pdf.
Glatz J, Muschalla B, Karger G. Patientenschulung bei Herzinsuffizienz verbessert krankheitsbezogenes Wissen und Verhalten während kardiologischer Rehabilitation. Rehabilitation (Stuttg) 2014; 53(3):155–60. DOI: 10.1055/s-0033-1351312. http://www.ncbi.nlm.nih.gov/pubmed/24390871.
Gold MR, Thebault C, Linde C, et al. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: Results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation 2012; 126(7):822–9. DOI: 10.1161/CIRCULATIONAHA.112.097709. http://www.ncbi.nlm.nih.gov/pubmed/22781424.
Goldenberg I, Kutyifa V, Klein HU, et al. Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 2014; 370(18):1694–701. DOI: 10.1056/NEJMoa1401426. http://www.ncbi.nlm.nih.gov/pubmed/24678999.
Goldstein D, Moskowitz AJ, Gelijns AC, et al. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med 2016; 374(4):344–53. DOI: 10.1056/NEJMoa1512913. http://www.ncbi.nlm.nih.gov/pubmed/26550689.
Gomes B, Calanzani N, Curiale V, et al. Effectiveness and cost-effectiveness of home palliative care services for adults with advanced illness and their caregivers. Cochrane Database Syst Rev 2013(6):CD007760. DOI: 10.1002/14651858.CD007760.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23744578.
Goncalves J, Pereira T. Inappropriate shocks in patients with ICDs: Single chamber versus dual chamber. Arq Bras Cardiol 2013; 101(2):141–8. DOI: 10.5935/abc.20130125. http://www.ncbi.nlm.nih.gov/pubmed/23821405.
Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362(9386):772–6. http://www.ncbi.nlm.nih.gov/pubmed/13678870.
Green AR, Boyd CM, Rickard J, et al. Attitudes of older adults with serious competing health risks toward their implantable cardioverter-defibrillators: A pilot study. BMC Geriatr 2015; 15:173. DOI: 10.1186/s12877-015-0173-2. http://www.ncbi.nlm.nih.gov/pubmed/26700296.
Green AR, Leff B, Wang Y, et al. Geriatric Conditions in Patients Undergoing Defibrillator Implantation for Prevention of Sudden Cardiac Death: Prevalence and Impact on Mortality. Circ Cardiovasc Qual Outcomes 2016; 9(1):23–30. DOI: 10.1161/CIRCOUTCOMES.115.002053. http://www.ncbi.nlm.nih.gov/pubmed/26715650.
Guillo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am. J. Cardiol. 1997; 79(9):1276–8. http://www.ncbi.nlm.nih.gov/pubmed/9164905.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: An emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336(7650):924–6. http://www.ncbi.nlm.nih.gov/pubmed/18436948.
Haas SJ, Vos T, Gilbert RE, et al. Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003; 146(5):848–53. http://www.ncbi.nlm.nih.gov/pubmed/14597934.
Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): An open-label, pilot, randomised trial. Lancet 2019; 393(10166):61–73. DOI: 10.1016/S0140-6736(18)32484-X. http://www.ncbi.nlm.nih.gov/pubmed/30429050.
Hancock HC, Close H, Mason JM, et al. High prevalence of undetected heart failure in long-term care residents: Findings from the Heart Failure in Care Homes (HFinCH) study. Eur J Heart Fail 2013; 15(2):158–65. DOI: 10.1093/eurjhf/hfs165. http://www.ncbi.nlm.nih.gov/pubmed/23112002.
Hauner H, Buchholz G, Hamann A, et al. Prävention und Therapie der Adipositas. Version 2.0. 2014 [cited: 2018-04-05]. http://www.awmf.org/uploads/tx_szleitlinien/050-001l_S3_Adipositas_Pr%C3%A4vention_Therapie_2014-11.pdf.
Havakuk O, King KS, Grazette L, et al. Heart Failure-Induced Brain Injury. J Am Coll Cardiol 2017; 69(12):1609–16. DOI: 10.1016/j.jacc.2017.01.022. http://www.ncbi.nlm.nih.gov/pubmed/28335844.
Health Quality Ontario (HQO). Left ventricular assist devices for destination therapy: A health technology assessment. 2016 [cited: 2017-01-10]. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761917/pdf/ohtas-16-1.pdf.
Heart Failure Clinical Research Network (HFN), Redfield MM, Chen HH, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial. JAMA 2013; 309(12):1268–77. DOI: 10.1001/jama.2013.2024. http://www.ncbi.nlm.nih.gov/pubmed/23478662.
Hegde SM, Claggett B, Shah AM, et al. Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist). Circulation 2017; 136(11):982–92. DOI: 10.1161/CIRCULATIONAHA.117.028002. http://www.ncbi.nlm.nih.gov/pubmed/28637881.
Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch. Intern. Med 2002; 162(15):1682–8. http://www.ncbi.nlm.nih.gov/pubmed/12153370.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145(18):e895-e1032. DOI: 10.1161/CIR.0000000000001063. http://www.ncbi.nlm.nih.gov/pubmed/35363499.
Heidenreich PA, Tsai V, Bao H, et al. Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? JACC Heart Fail 2015; 3(6):497–504. DOI: 10.1016/j.jchf.2015.01.012. http://www.ncbi.nlm.nih.gov/pubmed/25982109.
Heran BS, Musini VM, Bassett K, et al. Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev 2012; 4:CD003040. DOI: 10.1002/14651858.CD003040.pub2. http://www.ncbi.nlm.nih.gov/pubmed/22513909.
Herrmann-Lingen C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale - Deutsche Version (HADS-D). Manual. Berlin: Huber; 1993.
Herrmann-Lingen C., Buss U., Snaith R.P. Hospital Anxiety and Depression Scale - deutsche Version (HADS-D). 3rd ed. Bern: Huber; 2011.
Herzog A, Voigt K, Meyer B, et al. Der Fragebogen zum Erleben von Körperbeschwerden (SSEQ): Ein neues Selbstbeurteilungsinstrument zur Erfassung der psychischen Merkmale somatoformer Störungen. Psychother Psychosom Med Psychol 2014; 64(3-4):115–21. DOI: 10.1055/s-0032-1333303. http://www.ncbi.nlm.nih.gov/pubmed/23864304.
Hess PL, Al-Khatib SM, Han JY, et al. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: Does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes 2015; 8(2):179–86. DOI: 10.1161/CIRCOUTCOMES.114.001306. http://www.ncbi.nlm.nih.gov/pubmed/25669833.
Hicks BM, Filion KB, Yin H, et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: Population based cohort study. BMJ 2018; 363:k4209. DOI: 10.1136/bmj.k4209. http://www.ncbi.nlm.nih.gov/pubmed/30355745.
Hindricks G, Taborsky M, Glikson M, et al. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): A randomised controlled trial. Lancet 2014; 384(9943):583–90. DOI: 10.1016/S0140-6736(14)61176-4. http://www.ncbi.nlm.nih.gov/pubmed/25131977.
Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000; 283(10):1295–302. http://www.ncbi.nlm.nih.gov/pubmed/10714728.
Ho C, Li H, Noorani H, et al. Implantable cardiac defibrillators for primary prevention of sudden cardiac death in high risk patients: A meta-analysis of clinical efficacy, and a review of cost-effectiveness and psychosocial issues. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); 2007 (Technology report; 81). http://www.cadth.ca/media/pdf/332_ICD_tr_e.pdf.
Hobbs FD, Kenkre JE, Roalfe AK, et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J 2002; 23(23):1867–76. http://www.ncbi.nlm.nih.gov/pubmed/12445536.
Höfer S, Schmid JP, Frick M, et al. Psychometric properties of the MacNew heart disease health-related quality of life instrument in patients with heart failure. J Eval. Clin Pract. 2008; 14(4):500–6. http://www.ncbi.nlm.nih.gov/pubmed/18462292.
Hoffmann R. Positionspapier zu Qualitätsstandards in der Echokardiographie. Z Kardiol 2004; 93(12):975–86. http://www.ncbi.nlm.nih.gov/pubmed/15599574.
Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N. Engl. J Med 2004; 351(24):2481–8. http://www.ncbi.nlm.nih.gov/pubmed/15590950.
Homma S, Thompson JL, Pullicino PM, et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366(20):1859–69. DOI: 10.1056/NEJMoa1202299. http://www.ncbi.nlm.nih.gov/pubmed/22551105.
Hoppe JD. Grundsätze der Bundesärztekammer zur ärztlichen Sterbebegleitung. Dtsch Arztebl 2011; 108(7):A-346-8.
Horwich TB, Broderick S, Chen L, et al. Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure. Am J Cardiol 2011; 108(12):1754–9. DOI: 10.1016/j.amjcard.2011.07.051. http://www.ncbi.nlm.nih.gov/pubmed/21907317.
Houchen E, Loefroth E, Schlienger R, et al. Hospitalization Rates in Patients with Heart Failure and Reduced Ejection Fraction Initiating Sacubitril/Valsartan or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers: A Retrospective Cohort Study. Cardiol Ther 2022; 11(1):113–27. DOI: 10.1161/CIRCOUTCOMES.110.957225. http://www.ncbi.nlm.nih.gov/pubmed/35094306.
Hu LJ, Chen YQ, Deng SB, et al. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: A systematic review and meta-analysis. Br J Clin Pharmacol 2013; 75(5):1202–12. DOI: 10.1111/bcp.12012. http://www.ncbi.nlm.nih.gov/pubmed/23088367.
Hu ZY, Zhang J, Xu ZT, et al. Efficiencies and Complications of Dual Chamber versus Single Chamber Implantable Cardioverter Defibrillators in Secondary Sudden Cardiac Death Prevention: A Meta-analysis. Heart Lung Circ 2016; 25(2):148–54. DOI: 10.1016/j.hlc.2015.07.008. http://www.ncbi.nlm.nih.gov/pubmed/26338316.
Huibers MJ, Beurskens AJ, Bleijenberg G, et al. The effectiveness of psychosocial interventions delivered by general practitioners. Cochrane Database Syst Rev 2003(2):CD003494. DOI: 10.1002/14651858.CD003494. http://www.ncbi.nlm.nih.gov/pubmed/12804471.
Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112(12):e154-e235. http://www.ncbi.nlm.nih.gov/pubmed/16160202.
Hutcheon SD, Gillespie ND, Crombie IK, et al. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: A randomised double blind placebo controlled trial. Heart 2002; 88(4):373–7. http://www.ncbi.nlm.nih.gov/pubmed/12231595.
Inglis SC, Clark RA, Dierckx R, et al. Structured telephone support or non-invasive telemonitoring for patients with heart failure. Cochrane Database Syst Rev 2015(10):CD007228. DOI: 10.1002/14651858.CD007228.pub3. http://www.ncbi.nlm.nih.gov/pubmed/26517969.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sacubitril/Valsartan - Addendum zum Auftrag A15-60. Addendum. Auftrag A16-29. Version 1.0. 2016 (IQWiG-Berichte; 394) [cited: 2019-10-01]. https://www.iqwig.de/projekte/a16-29.html.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Sacubitril/Valsartan - Nutzenbewertung gemäβ § 35a SGB V. Dossierbewertung. Auftrag: A15-60. Version: 1.0. 2016 (IQWiG-Berichte; 379) [cited: 2019-10-01]. https://www.iqwig.de/projekte/a15-60.html.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Vericiguat (Herzinsuffizienz) – Nutzenbewertung gemäß § 35a SGB V. Dossierbewertung. Auftrag: A21-120. Version: 1.0. 2021 (IQWiG-Berichte; 1255) [cited: 2023-02-24]. https://www.iqwig.de/projekte/a21-120.html.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Vericiguat (Herzinsuffizienz) – Addendum zum Auftrag A21-120. Addendum. Auftrag A22-08. Version: 1.0. 2022 (IQWiG-Berichte; 1291) [cited: 2023-02-24]. https://www.iqwig.de/projekte/a22-08.html.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Telemonitoring mithilfe von aktiven kardialen implantierbaren Aggregaten bei ventrikulärer Tachyarrhythmie sowie Herzinsuffizienz. Abschlussbericht. N16-02. Version 1.2. 2018 (IQWiG-Berichte; 577) [cited: 2019-11-08]. https://www.iqwig.de/download/N16-02_Telemonitoring-mithilfe-von-aktiven-kardialen-implantierbaren-Aggregaten_Abschlussbericht_V1-2.pdf.
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Datengestütztes, zeitnahes Management in Zusammenarbeit mit einem ärztlichen telemedizinischen Zentrum bei fortgeschrittener Herzinsuffizienz. Rapid Report. Auftrag: N19-01. Version: 1.0. 2019 (IQWiG-Berichte; 822) [cited: 2019-11-21]. https://www.iqwig.de/download/N19-01_Telemonitoring-bei-fortgeschrittener-Herzinsuffizienz_Rapid-Report_V1-0.pdf.
Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG). Herzschrittmacher-Implantation. Qualitätsindikatoren. Bundesauswertung zum Erfassungsjahr 2015. 2016 [cited: 2019-10-01]. https://iqtig.org/downloads/auswertung/2015/09n1hsmimpl/QSKH_09n1-HSM-IMPL_2015_BUAW_V02_2016-07-07.pdf.
Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG). Implantierbare Defibrillatoren-Implantation. Qualitätsindikatoren. Bundesauswertung zum Erfassungsjahr 2015. 2016 [cited: 2019-10-01]. https://iqtig.org/downloads/auswertung/2015/09n4defiimpl/QSKH_09n4-DEFI-IMPL_2015_BUAW_V02_2016-07-07.pdf.
Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG). Implantierbare Defibrillatoren-Aggregatwechsel. Indikatoren 2015. Bundesauswertung zum Erfassungsjahr 2015. 2016 [cited: 2019-10-01]. https://iqtig.org/downloads/auswertung/2015/09n5defiaggw/QSKH_09n5-DEFI-AGGW_2015_QIDB_V01_2016-05-04.pdf.
Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG). Herzunterstützungssysteme/Kunstherzen. Qualitätsindikatoren. Bundesauswertung zum Erfassungsjahr 2015. 2016 [cited: 2019-10-01]. https://iqtig.org/downloads/auswertung/2015/htxmmku/QSKH_HTXM-MKU_2015_BUAW_V02_2016-07-07.pdf.
Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs). Quarterly Statistical Report. 2016 Q3. 2016 [cited: 2023-09-07]. https://intermacs.kirso.net/reports/quarterly-site-reports.
International Society for Heart & Lung Transplantation (ISHLT). ISHLT Transplant Registry Quarterly Reports for Heart in Europe. Survival Rates for Transplants performed between October 1, 2011 and September 30, 2015. 2016 [cited: 2017-01-30]. https://ishltregistries.org/registries/quarterlyDataReport.asp.
Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: A position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11(5):433–43. DOI: 10.1093/eurjhf/hfp041. http://www.ncbi.nlm.nih.gov/pubmed/19386813.
Jackson AM, Dewan P, Anand IS, et al. Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation 2020; 142(11):1040–54. DOI: 10.1161/CIRCULATIONAHA.120.047077. http://www.ncbi.nlm.nih.gov/pubmed/32673497.
Jacob AJ, McLaren KM, Boon NA. Effects of abstinence on alcoholic heart muscle disease. Am. J. Cardiol. 1991; 68(8):805–7. http://www.ncbi.nlm.nih.gov/pubmed/1892094.
Jankowska EA, Tkaczyszyn M, Suchocki T, et al. Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: A meta-analysis of randomized controlled trials. Eur J Heart Fail 2016; 18(7):786–95. DOI: 10.1002/ejhf.473. http://www.ncbi.nlm.nih.gov/pubmed/26821594.
Jewiss D, Ostman C, Smart NA. The effect of resistance training on clinical outcomes in heart failure: A systematic review and meta-analysis. Int J Cardiol 2016; 221:674–81. DOI: 10.1016/j.ijcard.2016.07.046. http://www.ncbi.nlm.nih.gov/pubmed/27423089.
Jeyanantham K, Kotecha D, Thanki D, et al. Effects of cognitive behavioural therapy for depression in heart failure patients: A systematic review and meta-analysis. Heart Fail Rev 2017; 22(6):731–41. DOI: 10.1007/s10741-017-9640-5. http://www.ncbi.nlm.nih.gov/pubmed/28733911.
Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: Insights from PARADIGM-HF. Eur Heart J 2015; 36(38):2576–84. DOI: 10.1093/eurheartj/ehv330. http://www.ncbi.nlm.nih.gov/pubmed/26231885.
Jones RH, Velazquez EJ, Michler RE, et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N. Engl. J Med 2009; 360(17):1705–17. http://www.ncbi.nlm.nih.gov/pubmed/19329820.
Jong P, Demers C, McKelvie RS, et al. Angiotensin receptor blockers in heart failure: Meta-analysis of randomized controlled trials. J Am Coll Cardiol 2002; 39(3):463–70. http://www.ncbi.nlm.nih.gov/pubmed/11823085.
Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: A population-based study. Arch. Intern. Med 2002; 162(15):1689–94. http://www.ncbi.nlm.nih.gov/pubmed/12153371.
Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: A follow-up study. Lancet 2003; 361(9372):1843–8. http://www.ncbi.nlm.nih.gov/pubmed/12788569.
Juenger J, Schellberg D, Kraemer S, et al. Health related quality of life in patients with congestive heart failure: Comparison with other chronic diseases and relation to functional variables. Heart 2002; 87(3):235–41. http://www.ncbi.nlm.nih.gov/pubmed/11847161.
Jung W, Andresen D, Block M, et al. Leitlinien zur Implantation von Defibrillatoren. Clin Res Cardiol 2006; 95(12):696–708. http://www.ncbi.nlm.nih.gov/pubmed/17103126.
Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J Med 2004; 351(6):543–51. http://www.ncbi.nlm.nih.gov/pubmed/15295047.
Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N. Engl. J Med 2004; 350(21):2151–8. http://www.ncbi.nlm.nih.gov/pubmed/15152060.
Kadish A, Nademanee K, Volosin K, et al. A randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failure. Am Heart J 2011; 161(2):329–37. DOI: 10.1016/j.ahj.2010.10.025. http://www.ncbi.nlm.nih.gov/pubmed/21315216.
Kaduszkiewicz H, Gerste B, Eisele M, et al. Herzinsuffizienz: Epidemiologie und Versorgung. In: Klauber J, Günster C, Gerste B, Robra B-P, Schmacke N, editors. Schwerpunkt: Depression. Stuttgart: Schattauer; 2014, p. 209–229.
Kaiser T, Jennen E, Sawicki PT. Entscheidungsgrundlage zur evidenzbasierten Diagnostik und Therapie bei Disease Management Programmen für Herzinsuffizienz bei systolischer linksventrikulärer Dysfunktion. 2., überarbeitete Version. Köln: DIeM; 2003.
Kalogeropoulos AP, Thankachen J, Butler J, et al. Diuretic and renal effects of spironolactone and heart failure hospitalizations: A TOPCAT Americas analysis. Eur J Heart Fail 2020; 22(9):1600–10. DOI: 10.1002/ejhf.1917. http://www.ncbi.nlm.nih.gov/pubmed/32469156.
Kane PM, Murtagh FE, Ryan K, et al. The gap between policy and practice: A systematic review of patient-centred care interventions in chronic heart failure. Heart Fail Rev 2015; 20(6):673–87. DOI: 10.1007/s10741-015-9508-5. http://www.ncbi.nlm.nih.gov/pubmed/26435042.
Kang JE, Han NY, Oh JM, et al. Pharmacist-involved care for patients with heart failure and acute coronary syndrome: A systematic review with qualitative and quantitative meta-analysis. J Clin Pharm Ther 2016; 41(2):145–57. DOI: 10.1111/jcpt.12367. http://www.ncbi.nlm.nih.gov/pubmed/26954666.
Kashour TS, Joury A, Alotaibi AM, et al. Quality of assessment and counselling offered by community pharmacists and medication sale without prescription to patients presenting with acute cardiac symptoms: A simulated client study. Eur J Clin Pharmacol 2016; 72(3):321–8. DOI: 10.1007/s00228-015-1981-1. http://www.ncbi.nlm.nih.gov/pubmed/26592495.
Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011; 124(25):2865–73. DOI: 10.1161/CIRCULATIONAHA.111.019216. http://www.ncbi.nlm.nih.gov/pubmed/22104551.
Keller K, Farmakis IT, Valerio L, et al. Predisposing factors for admission to intensive care units of patients with COVID-19 infection-Results of the German nationwide inpatient sample. Front Public Health 2023; 11:1113793. DOI: 10.1093/cid/ciaa1012. http://www.ncbi.nlm.nih.gov/pubmed/36875366.
Kidney Disease: Improving Global Outcomes (KDIGO), Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. 2012 (Kidney inter.; 2 Suppl) [cited: 2023-09-07]. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.
Kidney Disease: Improving Global Outcomes (KDIGO), CKD Work Group. KDIGO 2012. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2013 (Kidney inter.; 3 Suppl) [cited: 2023-09-07]. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf.
Kim BJ, Huang C-W, Chung J, et al. Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system. J Manag Care Spec Pharm 2022; 28(10):1173–9. DOI: 10.18553/jmcp.2022.28.10.1173. http://www.ncbi.nlm.nih.gov/pubmed/36125061.
Kini V, Soufi MK, Deo R, et al. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: Are indications still met? J Am Coll Cardiol 2014; 63(22):2388–94. DOI: 10.1016/j.jacc.2014.03.025. http://www.ncbi.nlm.nih.gov/pubmed/24727249.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38):2893–962. DOI: 10.1093/eurheartj/ehw210. http://www.ncbi.nlm.nih.gov/pubmed/27567408.
Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: An analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014; 35(18):1186–94. DOI: 10.1093/eurheartj/eht511. http://www.ncbi.nlm.nih.gov/pubmed/24347317.
Kirklin JK, Cantor R, Mohacsi P, et al. First Annual IMACS Report: A global International Society for Heart and Lung Transplantation Registry for Mechanical Circulatory Support. J Heart Lung Transplant 2016; 35(4):407–12. DOI: 10.1016/j.healun.2016.01.002. http://www.ncbi.nlm.nih.gov/pubmed/26922275.
Kitsiou S, Pare G, Jaana M. Effects of home telemonitoring interventions on patients with chronic heart failure: An overview of systematic reviews. J Med Internet Res 2015; 17(3):e63. DOI: 10.2196/jmir.4174. http://www.ncbi.nlm.nih.gov/pubmed/25768664.
Klauber J, Günster C, Gerste B, editors. Versorgungs-Report 2015/2016: Kinder und Jugendliche. Stuttgart: Schattauer; 2016.
Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am Heart J 2013; 165(4):575-582.e3. DOI: 10.1016/j.ahj.2013.01.017. http://www.ncbi.nlm.nih.gov/pubmed/23537975.
Kloka JA, Blum LV, Old O, et al. Characteristics and mortality of 561,379 hospitalized COVID-19 patients in Germany until December 2021 based on real-life data. Sci Rep 2022; 12(1):11116. DOI: 10.1161/JAHA.116.003638. http://www.ncbi.nlm.nih.gov/pubmed/35778464.
Kobe J, Andresen D, Maier S, et al. Complications and 1-year benefit of cardiac resynchronization therapy in patients over 75 years of age - Insights from the German Device Registry. Int J Cardiol 2016; 228:784–9. DOI: 10.1016/j.ijcard.2016.11.212. http://www.ncbi.nlm.nih.gov/pubmed/27898337.
Kober L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. N Engl J Med 2016; 375(13):1221–30. DOI: 10.1056/NEJMoa1608029. http://www.ncbi.nlm.nih.gov/pubmed/27571011.
Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333(25):1670–6. http://www.ncbi.nlm.nih.gov/pubmed/7477219.
Koberich S, Lohrmann C, Mittag O, et al. Effects of a hospital-based education programme on self-care behaviour, care dependency and quality of life in patients with heart failure—a randomised controlled trial. J Clin Nurs 2015; 24(11-12):1643–55. DOI: 10.1111/jocn.12766. http://www.ncbi.nlm.nih.gov/pubmed/25661470.
Koehler F, Koehler K, Deckwart O, et al. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): A randomised, controlled, parallel-group, unmasked trial. Lancet 2018; 392(10152):1047–57. DOI: 10.1016/S0140-6736(18)31880-4. http://www.ncbi.nlm.nih.gov/pubmed/30153985.
Koehler F, Winkler S, Schieber M, et al. Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: The telemedical interventional monitoring in heart failure study. Circulation 2011; 123(17):1873–80. DOI: 10.1161/CIRCULATIONAHA.111.018473. http://www.ncbi.nlm.nih.gov/pubmed/21444883.
Kopel E, Klempfner R, Goldenberg I. Influenza vaccine and survival in acute heart failure. Eur J Heart Fail 2014; 16(3):264–70. DOI: 10.1002/ejhf.14. http://www.ncbi.nlm.nih.gov/pubmed/24464586.
Koshman SL, Charrois TL, Simpson SH, et al. Pharmacist care of patients with heart failure: A systematic review of randomized trials. Arch. Intern. Med 2008; 168(7):687–94. DOI: 10.1001/archinte.168.7.687. http://www.ncbi.nlm.nih.gov/pubmed/18413550.
Kosiuk J, Lindemann F, Hindricks G, et al. Need for further studies on ivabradine in patients with persistent atrial fibrillation. Int J Cardiol 2016; 223:915–6. DOI: 10.1016/j.ijcard.2016.08.329. http://www.ncbi.nlm.nih.gov/pubmed/27589039.
Kosiuk J, Oebel S, John S, et al. Ivabradine for rate control in atrial fibrillation. Int J Cardiol 2015; 179:27–8. DOI: 10.1016/j.ijcard.2014.10.062. http://www.ncbi.nlm.nih.gov/pubmed/25464400.
Kotb A, Cameron C, Hsieh S, et al. Comparative effectiveness of different forms of telemedicine for individuals with heart failure (HF): A systematic review and network meta-analysis. PLoS. One. 2015; 10(2):e0118681. DOI: 10.1371/journal.pone.0118681. http://www.ncbi.nlm.nih.gov/pubmed/25714962.
Kotecha D, Holmes J, Krum H, et al. Efficacy of beta blockers in patients with heart failure plus atrial fibrillation: An individual-patient data meta-analysis. Lancet 2014; 384(9961):2235–43. http://www.ncbi.nlm.nih.gov/pubmed/25193873.
Kraigher-Krainer E, Lyass A, Massaro JM, et al. Association of physical activity and heart failure with preserved vs. reduced ejection fraction in the elderly: The Framingham Heart Study. Eur J Heart Fail 2013; 15(7):742–6. DOI: 10.1093/eurjhf/hft025. http://www.ncbi.nlm.nih.gov/pubmed/23435761.
Kristensen SL, Preiss D, Jhund PS, et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail 2016; 9(1):e002560. DOI: 10.1161/CIRCHEARTFAILURE.115.002560. http://www.ncbi.nlm.nih.gov/pubmed/26754626.
Kroenke K, Spitzer RL, Williams JB, et al. Anxiety disorders in primary care: Prevalence, impairment, comorbidity, and detection. Ann Intern Med 2007; 146(5):317–25. http://www.ncbi.nlm.nih.gov/pubmed/17339617.
Krum H, Gilbert RE. Demographics and concomitant disorders in heart failure. Lancet 2003; 362(9378):147–58. http://www.ncbi.nlm.nih.gov/pubmed/12867118.
Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: Results from the COPERNICUS Study. JAMA 2003; 289(6):712–8. http://www.ncbi.nlm.nih.gov/pubmed/12585949.
Kubota K, Kubota N, Pearce GL, et al. ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: Studies in prescription-event monitoring. Eur J Clin Pharmacol 1996; 49(6):431–7. http://www.ncbi.nlm.nih.gov/pubmed/8706766.
Kuck KH, Bordachar P, Borggrefe M, et al. New devices in heart failure: An European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association. Europace 2014; 16(1):109–28. DOI: 10.1093/europace/eut311. http://www.ncbi.nlm.nih.gov/pubmed/24265466.
Kuck KH, Cappato R, Siebels J, et al. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH). Circulation 2000; 102(7):748–54. http://www.ncbi.nlm.nih.gov/pubmed/10942742.
Kuske S, Lessing C, Lux R, et al. Patientensicherheitsindikatoren zur Arzneimitteltherapiesicherheit (AMTS-PSI): Internationaler Status, Übertragbarkeit und Validierung. Gesundheitswesen 2012; 74(2):79–86. DOI: 10.1055/s-0030-1269838. http://www.ncbi.nlm.nih.gov/pubmed/21229474.
Ladwig KH, Lederbogen F, Albus C, et al. Positionspapier zur Bedeutung psychosozialer Faktoren in der Kardiologie. Update 2013. Der Kardiologe 2013; 7(1):7–27. DOI: 10.1007/s12181-012-0478-8.
Lam SK, Owen A. Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials. BMJ 2007; 335(7626):925. http://www.ncbi.nlm.nih.gov/pubmed/17932160.
Lambrinou E, Kalogirou F, Lamnisos D, et al. Effectiveness of heart failure management programmes with nurse-led discharge planning in reducing re-admissions: A systematic review and meta-analysis. Int J Nurs Stud 2012; 49(5):610–24. DOI: 10.1016/j.ijnurstu.2011.11.002. http://www.ncbi.nlm.nih.gov/pubmed/22196054.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28(1):1-39.e14. DOI: 10.1016/j.echo.2014.10.003. http://www.ncbi.nlm.nih.gov/pubmed/25559473.
Large S. Surgery for heart failure. Heart 2007; 93(3):392–402. http://www.ncbi.nlm.nih.gov/pubmed/17322524.
Laufs U, Böhm M, Kroemer HK, et al. Strategien zur Verbesserung der Einnahmetreue von Medikamenten. Dtsch Med Wochenschr 2011; 136(31-32):1616–21. http://www.ncbi.nlm.nih.gov/pubmed/21809255.
Lavie CJ, Cahalin LP, Chase P, et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc 2013; 88(3):251–8. DOI: 10.1016/j.mayocp.2012.11.020. http://www.ncbi.nlm.nih.gov/pubmed/23489451.
Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002; 23(22):1780–7. http://www.ncbi.nlm.nih.gov/pubmed/12419298.
Lee D, Mansi I, Bhushan S, Parish R. Non-Adherence in At-Risk Heart Failure Patients: Characteristics and Outcomes. Journal of Nature and Science (JNSCI) 2015; 1(5):e95. http://www.jnsci.org/files/article/e95.pdf.
Lee VC, Rhew DC, Dylan M, et al. Meta-analysis: Angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med 2004; 141(9):693–704. http://www.ncbi.nlm.nih.gov/pubmed/15520426.
Lee VW, Choi LM, Wong WJ, et al. Pharmacist intervention in the prevention of heart failure for high-risk elderly patients in the community. BMC Cardiovasc Disord 2015; 15:178. DOI: 10.1186/s12872-015-0173-3. http://www.ncbi.nlm.nih.gov/pubmed/26702612.
Leigh-Hunt N, Bagguley D, Bash K, et al. An overview of systematic reviews on the public health consequences of social isolation and loneliness. Public Health 2017; 152:157–71. DOI: 10.1016/j.puhe.2017.07.035. http://www.ncbi.nlm.nih.gov/pubmed/28915435.
Leitlinienprogramm Onkologie (OL), Deutsche Krebsgesellschaft (DKG), Deutsche Krebshilfe, et al. Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung, Langversion 2.0. 2019 [cited: 2023-09-07]. https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Palliativmedizin/Version_2/LL_Palliativmedizin_2.0_Langversion.pdf.
Lewis GD, Malhotra R, Hernandez AF, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA 2017; 317(19):1958–66. DOI: 10.1001/jama.2017.5427. http://www.ncbi.nlm.nih.gov/pubmed/28510680.
Li Y, Fu B, Qian X. Liberal versus restricted fluid administration in heart failure patients. A systematic review and meta-analysis of randomized trials. Int Heart J 2015; 56(2):192–5. DOI: 10.1536/ihj.14-288. http://www.ncbi.nlm.nih.gov/pubmed/25740394.
Linde C, Abraham WT, Gold MR, et al. Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. J Am Coll Cardiol 2008; 52(23):1834–43. http://www.ncbi.nlm.nih.gov/pubmed/19038680.
Linde C, Gold MR, Abraham WT, et al. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J 2013; 34(33):2592–9. DOI: 10.1093/eurheartj/eht160. http://www.ncbi.nlm.nih.gov/pubmed/23641006.
Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: Results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002; 40(1):111–8. http://www.ncbi.nlm.nih.gov/pubmed/12103264.
Linde C, Stahlberg M, Benson L, et al. Gender, underutilization of cardiac resynchronization therapy, and prognostic impact of QRS prolongation and left bundle branch block in heart failure. Europace 2015; 17(3):424–31. DOI: 10.1093/europace/euu205. http://www.ncbi.nlm.nih.gov/pubmed/25164429.
Lip GY, Gibbs CR, Beevers DG. ABC of heart failure: Aetiology. Br Med J 2000; 320(7227):104–7. http://www.ncbi.nlm.nih.gov/pubmed/10625270.
Lip GY, Ponikowski P, Andreotti F, et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 2012; 14(7):681–95. DOI: 10.1093/eurjhf/hfs073. http://www.ncbi.nlm.nih.gov/pubmed/22611046.
Lip GY, Shantsila E. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev 2014(3):CD003336. DOI: 10.1002/14651858.CD003336.pub3. http://www.ncbi.nlm.nih.gov/pubmed/24683002.
Lopes C, Pereira T, Barra S. Cardiac resynchronization therapy in patients with atrial fibrillation: A meta-analysis. Rev Port. Cardiol 2014; 33(11):717–25. DOI: 10.1016/j.repc.2014.05.008. http://www.ncbi.nlm.nih.gov/pubmed/25457476.
Löwe B, Decker O, Müller S, et al. Validation and standardization of the Generalized Anxiety Disorder Screener (GAD-7) in the general population. Med Care 2008; 46(3):266–74. DOI: 10.1097/MLR.0b013e318160d093. http://www.ncbi.nlm.nih.gov/pubmed/18388841.
Löwe B, Spitzer RL, Gräfe K, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians‘ diagnoses. J Affect. Disord 2004; 78(2):131–40. http://www.ncbi.nlm.nih.gov/pubmed/14706723.
Löwe B, Spitzer RL, Zipfel S, et al. PHQ-D - Gesundheitsfragebogen für Patienten. Karlsruhe: Pfizer; 2001.
Lowrie R, Johansson L, Forsyth P, et al. Experiences of a community pharmacy service to support adherence and self-management in chronic heart failure. Int J Clin Pharm 2014; 36(1):154–62. DOI: 10.1007/s11096-013-9889-2. http://www.ncbi.nlm.nih.gov/pubmed/24293306.
Lozano I, Bocchiardo M, Achtelik M, et al. Impact of biventricular pacing on mortality in a randomized crossover study of patients with heart failure and ventricular arrhythmias. Pacing Clin Electrophysiol. 2000; 23(11 Pt 2):1711–2. http://www.ncbi.nlm.nih.gov/pubmed/11139906.
Luna CM, Palma I, Niederman MS, et al. The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-acquired Pneumonia. Ann Am Thorac Soc 2016; 13(9):1519–26. DOI: 10.1513/AnnalsATS.201512-848OC. http://www.ncbi.nlm.nih.gov/pubmed/27398827.
Lund LH, Claggett B, Liu J, et al. Heart failure with mid-range ejection fraction in CHARM: Characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018; 20(8):1230–9. DOI: 10.1002/ejhf.1149. http://www.ncbi.nlm.nih.gov/pubmed/29431256.
Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34(10):1244–54. DOI: 10.1016/j.healun.2015.08.003. http://www.ncbi.nlm.nih.gov/pubmed/26454738.
Lund LH, Zeymer U, Clark AL, et al. Association between sacubitril/valsartan initiation and changes in left ventricular ejection fraction: Insights from ARIADNE registry. Int J Cardiol 2023; 370:279–86. DOI: 10.1016/j.ijcard.2022.10.012. http://www.ncbi.nlm.nih.gov/pubmed/36216094.
Luthje L, Vollmann D, Seegers J, et al. A randomized study of remote monitoring and fluid monitoring for the management of patients with implanted cardiac arrhythmia devices. Europace 2015; 17(8):1276–81. DOI: 10.1093/europace/euv039. http://www.ncbi.nlm.nih.gov/pubmed/25983310.
M AN, Aggarwal S, Reddy YN, et al. Surgical Repair of Moderate Ischemic Mitral Regurgitation-A Systematic Review and Meta-analysis. Thorac Cardiovasc Surg 2017; 65(6):447–56. DOI: 10.1055/s-0036-1598012. http://www.ncbi.nlm.nih.gov/pubmed/28109210.
Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: Cause or confounding? Br J Clin Pharmacol 1999; 47(1):111–4. http://www.ncbi.nlm.nih.gov/pubmed/10073748.
Maercker A, Schützwohl M. Erfassung von psychischen Belastungsfolgen: Die Impact of Event Skala-revidierte Version (IES-R)). Diagnostica 1998; 44(3):130–41.
Maggioni AP, Clark AL, Barrios V, et al. Outcomes with sacubitril/valsartan in outpatients with heart failure and reduced ejection fraction: The ARIADNE registry. ESC Heart Fail 2022; 9(6):4209–18. DOI: 10.1002/ehf2.14014. http://www.ncbi.nlm.nih.gov/pubmed/36106548.
Mant J, Doust J, Roalfe A, et al. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol Assess 2009; 13(32):1-207, iii. http://www.ncbi.nlm.nih.gov/pubmed/19586584.
Martin N, Manoharan K, Davies C, et al. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database Syst Rev 2021; 5(5):CD012721. DOI: 10.1002/14651858.CD012721.pub2. http://www.ncbi.nlm.nih.gov/pubmed/34022072.
Martin RI, Pogoryelova O, Koref MS, et al. Atrial fibrillation associated with ivabradine treatment: Meta-analysis of randomised controlled trials. Heart 2014; 100(19):1506–10. DOI: 10.1136/heartjnl-2014-305482. http://www.ncbi.nlm.nih.gov/pubmed/24951486.
Martinez FA, Serenelli M, Nicolau JC, et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. Circulation 2020; 141(2):100–11. DOI: 10.1161/CIRCULATIONAHA.119.044133. http://www.ncbi.nlm.nih.gov/pubmed/31736328.
Mattila M, Boehm L, Burke S, et al. Nonprescription medication use in patients with heart failure: Assessment methods, utilization patterns, and discrepancies with medical records. J Card Fail 2013; 19(12):811–5. DOI: 10.1016/j.cardfail.2013.10.009. http://www.ncbi.nlm.nih.gov/pubmed/24184371.
McAlister FA, Ezekowitz J, Dryden DM, et al. Cardiac resynchronization therapy and implantable cardiac defibrillators in left ventricular systolic dysfunction. Evid Rep Technol Assess (Full Rep) 2007(152):1–199. http://www.ncbi.nlm.nih.gov/pubmed/17764218.
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021; 42(36):3599–726. DOI: 10.1093/eurheartj/ehab368. http://www.ncbi.nlm.nih.gov/pubmed/34447992.
McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023:[Epub ahead of print]. DOI: 10.1093/eurheartj/ehad195. http://www.ncbi.nlm.nih.gov/pubmed/37622666.
McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100(10):1056–64. http://www.ncbi.nlm.nih.gov/pubmed/10477530.
McLellan J, Heneghan CJ, Perera R, et al. B-type natriuretic peptide-guided treatment for heart failure. Cochrane Database Syst Rev 2016; 12(12):CD008966. DOI: 10.1002/14651858.CD008966.pub2. http://www.ncbi.nlm.nih.gov/pubmed/28102899.
McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11):993–1004. DOI: 10.1056/NEJMoa1409077. http://www.ncbi.nlm.nih.gov/pubmed/25176015.
McMurray JJ, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019. DOI: 10.1056/NEJMoa1911303. http://www.ncbi.nlm.nih.gov/pubmed/31535829.
McMurray JJ. Sacubitril/valsartan and cognitive function in HFmrEF and HFpEF: Hot Line Session 1, ESC Congress 2022, Barcelona, Spain, 26–29 August. 2022 [cited: 2023-03-13]. https://esc365.escardio.org/presentation/255268?query=sacubitril%20perspective.
Mebazaa A, Davison B, Chioncel O, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial. Lancet 2022; 400(10367):1938–52. DOI: 10.1016/S0140-6736(22)02076-1. http://www.ncbi.nlm.nih.gov/pubmed/36356631.
Mehra MR, Naka Y, Uriel N, et al. A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. N Engl J Med 2017; 376(5):440–50. DOI: 10.1056/NEJMoa1610426. http://www.ncbi.nlm.nih.gov/pubmed/27959709.
Meinertz T, Hamm C, Schlensak C, et al. Deutscher Herzbericht 2017: 29. Sektorenübergreifende Versorgungsanalyse zur Kardiologie, Herzchirurgie und Kinderherzmedizin in Deutschland. Frankfurt: Deutsche Herzstiftung; 2017.
Meng K, Musekamp G, Schuler M, et al. The impact of a self-management patient education program for patients with chronic heart failure undergoing inpatient cardiac rehabilitation. Patient Educ Couns. 2016; 99(7):1190–7. DOI: 10.1016/j.pec.2016.02.010. http://www.ncbi.nlm.nih.gov/pubmed/26898600.
Menicanti L, Di Donato M. Left Ventricular Restoration: How Important is the Surgical Treatment of Ischemic Heart Failure Trial? Heart Fail Clin 2007; 3(2):237–43. http://www.ncbi.nlm.nih.gov/pubmed/17643924.
Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA 2023; 329(3):214–23. DOI: 10.1001/jama.2022.23924. http://www.ncbi.nlm.nih.gov/pubmed/36648467.
Merchant FM, Jones P, Wehrenberg S, et al. Incidence of defibrillator shocks after elective generator exchange following uneventful first battery life. J Am Heart Assoc 2014; 3(6):e001289. DOI: 10.1161/JAHA.114.001289. http://www.ncbi.nlm.nih.gov/pubmed/25385346.
MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353(9169):2001–7. http://www.ncbi.nlm.nih.gov/pubmed/10376614.
Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: A joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol 2013; 20(3):442–67. DOI: 10.1177/2047487312460484. http://www.ncbi.nlm.nih.gov/pubmed/23104970.
Michalsen A, König G, Thimme W. Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998; 80(5):437–41. http://www.ncbi.nlm.nih.gov/pubmed/9930040.
Michler RE, Rouleau JL, Al-Khalidi HR, et al. Insights from the STICH trial: Change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction. J Thorac Cardiovasc Surg 2013; 146(5):1139–45. DOI: 10.1016/j.jtcvs.2012.09.007. http://www.ncbi.nlm.nih.gov/pubmed/23111018.
Michler RE, Smith PK, Parides MK, et al. Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation. N Engl J Med 2016; 374(20):1932–41. DOI: 10.1056/NEJMoa1602003. http://www.ncbi.nlm.nih.gov/pubmed/27040451.
Mihos CG, Larrauri-Reyes M, Santana O. A Meta-Analysis of Ring Annuloplasty Versus Combined Ring Annuloplasty and Subvalvular Repair for Moderate-to-Severe Functional Mitral Regurgitation. J Card Surg 2016; 31(1):31–7. DOI: 10.1111/jocs.12662. http://www.ncbi.nlm.nih.gov/pubmed/26626776.
Miller RJ, Howlett JG, Exner DV, et al. Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis. Can J Cardiol 2015; 31(6):792–9. DOI: 10.1016/j.cjca.2014.12.031. http://www.ncbi.nlm.nih.gov/pubmed/26022990.
Minhas AM, Ahmed S, Khan MS, et al. Does Hemodynamic-Guided Heart Failure Management Reduce Hospitalization? A Systematic Review. Cureus. 2017; 9(4):e1161. DOI: 10.7759/cureus.1161. http://www.ncbi.nlm.nih.gov/pubmed/28507833.
Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2013(1):CD000422. DOI: 10.1002/14651858.CD000422.pub3. http://www.ncbi.nlm.nih.gov/pubmed/23440780.
Modin D, Jørgensen ME, Gislason G, et al. Influenza Vaccine in Heart Failure: Cumulative Number of Vaccinations, Frequency, Timing, and Survival: A Danish Nationwide Cohort Study. Circulation 2018; 139(5):575-586. DOI: 10.1161/CIRCULATIONAHA.118.036788. http://www.ncbi.nlm.nih.gov/pubmed/30586760.
Mohseni H, Kiran A, Khorshidi R, et al. Influenza vaccination and risk of hospitalization in patients with heart failure: A self-controlled case series study. Eur Heart J 2017; 38(5):326–33. DOI: 10.1093/eurheartj/ehw411. http://www.ncbi.nlm.nih.gov/pubmed/27660378.
Morfeld M, Kirchberger I, Bullinger M. SF-36. Fragebogen zum Gesundheitszustand. 2nd ed. Göttingen: Hogrefe; 2011.
Morris DA, Vaz Perez A, Blaschke F, et al. Myocardial systolic and diastolic consequences of left ventricular mechanical dyssynchrony in heart failure with normal left ventricular ejection fraction. Eur Heart J Cardiovasc Imaging 2012; 13(7):556–67. DOI: 10.1093/ehjci/jes042. http://www.ncbi.nlm.nih.gov/pubmed/22383372.
Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009; 361(14):1329–38. DOI: 10.1056/NEJMoa0906431. http://www.ncbi.nlm.nih.gov/pubmed/19723701.
Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335(26):1933–40. http://www.ncbi.nlm.nih.gov/pubmed/8960472.
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J Med 2002; 346(12):877–83. http://www.ncbi.nlm.nih.gov/pubmed/11907286.
Mueller PS, Swetz KM, Freeman MR, et al. Ethical analysis of withdrawing ventricular assist device support. Mayo Clin Proc 2010; 85(9):791–7. DOI: 10.4065/mcp.2010.0113. http://www.ncbi.nlm.nih.gov/pubmed/20584919.
Munir MB, Althouse AD, Rijal S, et al. Clinical Characteristics and Outcomes of Older Cardiac Resynchronization Therapy Recipients Using a Pacemaker versus a Defibrillator. J Cardiovasc Electrophysiol. 2016; 27(6):730–4. DOI: 10.1111/jce.12951. http://www.ncbi.nlm.nih.gov/pubmed/26856440.
Murray MD, Young J, Hoke S, et al. Pharmacist intervention to improve medication adherence in heart failure: A randomized trial. Ann Intern Med 2007; 146(10):714–25. http://www.ncbi.nlm.nih.gov/pubmed/17502632.
Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, et al. Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. Br Med J 1995; 310(6977):441–5. http://www.ncbi.nlm.nih.gov/pubmed/7873952.
Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016; 29(4):277–314. DOI: 10.1016/j.echo.2016.01.011. http://www.ncbi.nlm.nih.gov/pubmed/27037982.
Nappi F, Lusini M, Spadaccio C, et al. Papillary Muscle Approximation Versus Restrictive Annuloplasty Alone for Severe Ischemic Mitral Regurgitation. J Am Coll Cardiol 2016; 67(20):2334–46. DOI: 10.1016/j.jacc.2016.03.478. http://www.ncbi.nlm.nih.gov/pubmed/27199056.
National Institute for Health and Care Excellence (NICE). Acute heart failure: diagnosing and managing acute heart failure in adults. 2014 (NICE Clinical Guideline; 187) [cited: 2018-11-09]. http://www.nice.org.uk/guidance/cg187/resources/acute-heart-failure-diagnosis-and-management-pdf-35109817738693.
National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults. Diagnosis and management. 2018 (NICE Clinical Guideline; 106) [cited: 2018-10-09]. http://www.nice.org.uk/guidance/ng106/resources/chronic-heart-failure-in-adults-diagnosis-and-management-pdf-66141541311685.
National Institute for Health and Care Excellence (NICE). Surveillance programme Surveillance proposal consultation document Acute heart failure NICE guideline CG187 – 2017 surveillance review. 2017 (NICE Clinical Guideline; 187) [cited: 2023-09-07]. https://www.nice.org.uk/guidance/cg187.
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377(7):644–57. DOI: 10.1056/NEJMoa1611925. http://www.ncbi.nlm.nih.gov/pubmed/28605608.
Nesti L, Pugliese NR, Sciuto P, et al. Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: Results of the EMPA-HEART trial. Cardiovasc Diabetol 2022; 21(1):181. DOI: 10.1136/heartjnl-2019-316215. http://www.ncbi.nlm.nih.gov/pubmed/36096863.
Neyt M, Leroy R, Devos C, et al. Left ventricular assist devices in the treatment of end-stage heart failure. 2016 [cited: 2023-09-07]. https://kce.fgov.be/sites/default/files/2021-11/KCE_264_LVAD_report.pdf.
Nicolas JM, Fernandez-Sola J, Estruch R, et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med 2002; 136(3):192–200. http://www.ncbi.nlm.nih.gov/pubmed/11827495.
Nixdorff U, Buck T, Engberding R, et al. Positionspapier zur Qualifikation und Zertifizierung von Untersuchern in der Echokardiographie. Clin Res Cardiol. Suppl 2006; 1(S2):96–102.
Novartis Pharma, Rote Liste/Fachinfo-Service. Entresto® Filmtabletten. Fachinformation. 2016 [cited: 2017-02-22]. http://www.fachinfo.de.
Novartis Pharmaceuticals. Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction (PERSPECTIVE): NCT02884206. 2016 [cited: 2023-03-03]. https://clinicaltrials.gov/ct2/show/NCT02884206.
O‘Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010; 56(9):692–9. DOI: 10.1016/j.jacc.2010.03.068. http://www.ncbi.nlm.nih.gov/pubmed/20723799.
O‘Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301(14):1439–50. http://www.ncbi.nlm.nih.gov/pubmed/19351941.
Oga EA, Eseyin OR. The Obesity Paradox and Heart Failure: A Systematic Review of a Decade of Evidence. J Obes 2016; 2016:9040248. DOI: 10.1155/2016/9040248. http://www.ncbi.nlm.nih.gov/pubmed/26904277.
Ohlmeier C, Mikolajczyk R, Frick J, et al. Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: A study based on electronic healthcare data of more than six million persons. Clin Res Cardiol 2015; 104(8):688–96. DOI: 10.1007/s00392-015-0841-4. http://www.ncbi.nlm.nih.gov/pubmed/25777937.
Olde Nordkamp LR, Knops RE, Bardy GH, et al. Rationale and design of the PRAETORIAN trial: A Prospective, RAndomizEd comparison of subcuTaneOus and tRansvenous ImplANtable cardioverter-defibrillator therapy. Am Heart J 2012; 163(5):753–60. DOI: 10.1016/j.ahj.2012.02.012. http://www.ncbi.nlm.nih.gov/pubmed/22607851.
Opasich C, Febo O, Riccardi PG, et al. Concomitant factors of decompensation in chronic heart failure. Am. J. Cardiol. 1996; 78(3):354–7. http://www.ncbi.nlm.nih.gov/pubmed/8759821.
Ostgathe C, Alt-Epping B, Golla H, et al. Non-cancer patients in specialized palliative care in Germany: What are the problems? Palliat Med 2011; 25(2):148–52. DOI: 10.1177/0269216310385370. http://www.ncbi.nlm.nih.gov/pubmed/20937612.
Ostman C, Jewiss D, Smart NA. The Effect of Exercise Training Intensity on Quality of Life in Heart Failure Patients: A Systematic Review and Meta-Analysis. Cardiology 2017; 136(2):79–89. DOI: 10.1159/000448088. http://www.ncbi.nlm.nih.gov/pubmed/27577715.
Ouwerkerk W, Voors AA, Zwinderman AH. Factors influencing the predictive power of models for predicting mortality and/or heart failure hospitalization in patients with heart failure. JACC Heart Fail 2014; 2(5):429–36. DOI: 10.1016/j.jchf.2014.04.006. http://www.ncbi.nlm.nih.gov/pubmed/25194294.
Oyanguren J, Latorre García PM, Torcal Laguna J, et al. Effectiveness and Factors Determining the Success of Management Programs for Patients With Heart Failure: A Systematic Review and Meta-analysis. Rev Esp Cardiol (Engl Ed) 2016; 69(10):900–14. DOI: 10.1016/j.rec.2016.05.012. http://www.ncbi.nlm.nih.gov/pubmed/27692124.
Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020; 383(15):1413–24. DOI: 10.1056/NEJMoa2022190. http://www.ncbi.nlm.nih.gov/pubmed/32865377.
Packer M, Anker SD, Butler J, et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation 2021; 143(4):326–36. DOI: 10.1161/CIRCULATIONAHA.120.051783. http://www.ncbi.nlm.nih.gov/pubmed/33081531.
Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: The EMPEROR-Reduced trial. Eur Heart J 2021; 42(6):671–80. DOI: 10.1093/eurheartj/ehaa968. http://www.ncbi.nlm.nih.gov/pubmed/33459776.
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334(21):1349–55. http://www.ncbi.nlm.nih.gov/pubmed/8614419.
Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344(22):1651–8. http://www.ncbi.nlm.nih.gov/pubmed/11386263.
Packer M. Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure. JACC Heart Fail 2023; 11(1):106–14. DOI: 10.1016/j.jchf.2022.10.004. http://www.ncbi.nlm.nih.gov/pubmed/36396554.
Padeletti L, Arnar DO, Boncinelli L, et al. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy. Europace 2010; 12(10):1480–9. DOI: 10.1093/europace/euq275. http://www.ncbi.nlm.nih.gov/pubmed/20675674.
Padwal R, McAlister FA, McMurray JJ, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: A meta-analysis of individual patient data. Int J Obes (Lond) 2014; 38(8):1110–4. DOI: 10.1038/ijo.2013.203. http://www.ncbi.nlm.nih.gov/pubmed/24173404.
Page RL, O‘Bryant CL, Cheng D, et al. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation 2016; 134(6):e32-e69. DOI: 10.1161/CIR.0000000000000426. http://www.ncbi.nlm.nih.gov/pubmed/27400984.
Palau P, Nunez E, Dominguez E, et al. Physical therapy in heart failure with preserved ejection fraction: A systematic review. Eur J Prev Cardiol 2016; 23(1):4–13. DOI: 10.1177/2047487314562740. http://www.ncbi.nlm.nih.gov/pubmed/25488549.
Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: Meta-analysis of randomized control trials. Circ Heart Fail 2015; 8(1):33–40. DOI: 10.1161/CIRCHEARTFAILURE.114.001615. http://www.ncbi.nlm.nih.gov/pubmed/25399909.
Parker JO. The effects of oral ibopamine in patients with mild heart failure—a double blind placebo controlled comparison to furosemide. The Ibopamine Study Group. Int J Cardiol 1993; 40(3):221–7. DOI: 10.1016/0167-5273(93)90004-z. http://www.ncbi.nlm.nih.gov/pubmed/8225657.
Pascual-Figal D, Wachter R, Senni M, et al. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study. JACC Heart failure 2020; 8(10):822–33. DOI: 10.1016/j.jchf.2020.05.012. http://www.ncbi.nlm.nih.gov/pubmed/32800508.
Patterson JH, Adams KF, Applefeld MM, et al. Oral torsemide in patients with chronic congestive heart failure: Effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 1994; 14(5):514–21. http://www.ncbi.nlm.nih.gov/pubmed/7997385.
Pedersen SA, Gaist D, Schmidt SA, et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78(4):673-681.e9. DOI: 10.1016/j.jaad.2017.11.042. http://www.ncbi.nlm.nih.gov/pubmed/29217346.
Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380(24):2295–306. DOI: 10.1056/NEJMoa1811744. http://www.ncbi.nlm.nih.gov/pubmed/30990260.
Peters-Klimm F, Campbell S, Hermann K, et al. Case management for patients with chronic systolic heart failure in primary care: The HICMan exploratory randomised controlled trial. Trials 2010; 11:56. DOI: 10.1186/1745-6215-11-56. http://www.ncbi.nlm.nih.gov/pubmed/20478035.
Petrone AB, Gaziano JM, Djoussé L. Alcohol consumption and risk of death in male physicians with heart failure. Am J Cardiol 2014; 114(7):1065–8. DOI: 10.1016/j.amjcard.2014.07.021. http://www.ncbi.nlm.nih.gov/pubmed/25129877.
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327(10):669–77. http://www.ncbi.nlm.nih.gov/pubmed/1386652.
Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med 2021; 385(20):1845–55. DOI: 10.1056/NEJMoa2104508. http://www.ncbi.nlm.nih.gov/pubmed/34758252.
Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349(20):1893–906. http://www.ncbi.nlm.nih.gov/pubmed/14610160.
Philbin EF, Weil HF, Erb TA, et al. Cardiology or primary care for heart failure in the community setting: Process of care and clinical outcomes. Chest 1999; 116(2):346–54. http://www.ncbi.nlm.nih.gov/pubmed/10453861.
Piepoli MF, Corrà U, Veglia F, et al. Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: Data from the MECKI Score Research Group. Eur J Heart Fail 2016; 18(5):545–53. DOI: 10.1002/ejhf.534. http://www.ncbi.nlm.nih.gov/pubmed/27135769.
Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29):2315–81. DOI: 10.1093/eurheartj/ehw106. http://www.ncbi.nlm.nih.gov/pubmed/27222591.
Pitcher D, Soar J, Hogg K, et al. Cardiovascular implanted electronic devices in people towards the end of life, during cardiopulmonary resuscitation and after death: Guidance from the Resuscitation Council (UK), British Cardiovascular Society and National Council for Palliative Care. Heart 2016; 102 Suppl 7:A1-A17. DOI: 10.1136/heartjnl-2016-309721. http://www.ncbi.nlm.nih.gov/pubmed/27277710.
Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355(9215):1582–7. http://www.ncbi.nlm.nih.gov/pubmed/10821361.
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J Med 2003; 348(14):1309–21. http://www.ncbi.nlm.nih.gov/pubmed/12668699.
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10):709–17. http://www.ncbi.nlm.nih.gov/pubmed/10471456.
Pletz MW, Rohde G, Schutte H, et al. Epidemiologie und Erreger bei ambulant erworbener Pneumonie (CAP). Dtsch Med Wochenschr 2011; 136(15):775–80. DOI: 10.1055/s-0031-1275806. http://www.ncbi.nlm.nih.gov/pubmed/21469047.
Pocock SJ, Ariti CA, McMurray JJ, et al. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34(19):1404–13. DOI: 10.1093/eurheartj/ehs337. http://www.ncbi.nlm.nih.gov/pubmed/23095984.
Ponikowski P, Anker S, Voors AA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2016 // 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology. Developed with the special contribution Heart Failure Association (HFA) of the ESC // The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27):2129–200. DOI: 10.1093/eurheartj/ehw128. http://www.ncbi.nlm.nih.gov/pubmed/27206819.
Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: Results from the REPLACE registry. Circulation 2010; 122(16):1553–61. DOI: 10.1161/CIRCULATIONAHA.110.976076. http://www.ncbi.nlm.nih.gov/pubmed/20921437.
Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 2003; 362(9377):7–13. http://www.ncbi.nlm.nih.gov/pubmed/12853193.
Pottegård A, Hallas J, Olesen M, et al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282(4):322–31. DOI: 10.1111/joim.12629. http://www.ncbi.nlm.nih.gov/pubmed/28480532.
Potter E, Stephenson G, Harris J, et al. Screening-guided spironolactone treatment of subclinical left ventricular dysfunction for heart failure prevention in at-risk patients. Eur J Heart Fail 2022; 24(4):620–30. DOI: 10.1002/ejhf.2428. http://www.ncbi.nlm.nih.gov/pubmed/35014128.
Prins KW, Neill JM, Tyler JO, et al. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. JACC Heart Fail 2015; 3(8):647–53. DOI: 10.1016/j.jchf.2015.03.008. http://www.ncbi.nlm.nih.gov/pubmed/26251094.
Psotka MA, Maltzahn R von, Anatchkova M, et al. Patient-Reported Outcomes in Chronic Heart Failure: Applicability for Regulatory Approval. JACC Heart Fail 2016; 4(10):791–804. DOI: 10.1016/j.jchf.2016.04.010. http://www.ncbi.nlm.nih.gov/pubmed/27395351.
Qaseem A, Forland F, Macbeth F, et al. Guidelines International Network: Toward International Standards for Clinical Practice Guidelines. Ann Intern Med 2012; 156(7):525–31. http://www.ncbi.nlm.nih.gov/pubmed/22473437.
Qian C, Wei B, Ding J, et al. The Efficacy and Safety of Iron Supplementation in Patients With Heart Failure and Iron Deficiency: A Systematic Review and Meta-analysis. Can J Cardiol 2016; 32(2):151–9. DOI: 10.1016/j.cjca.2015.06.009. http://www.ncbi.nlm.nih.gov/pubmed/26454467.
Quality of Care and Outcomes Research (QCOR), Heart Failure Society of America (HFSA)Goodlin, S., Dolansky M, et al. Heart failure management in skilled nursing facilities: A scientific statement from the American Heart Association and the Heart Failure Society of America. Circ Heart Fail 2015; 8(3):655–87. DOI: 10.1161/HHF.0000000000000005. http://www.ncbi.nlm.nih.gov/pubmed/25855686.
Rahimi K, Bennett D, Conrad N, et al. Risk prediction in patients with heart failure: A systematic review and analysis. JACC Heart Fail 2014; 2(5):440–6. DOI: 10.1016/j.jchf.2014.04.008. http://www.ncbi.nlm.nih.gov/pubmed/25194291.
Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Australia/New Zealand Heart Failure Research Collaborative Group. Lancet 1997; 349(9049):375–80. http://www.ncbi.nlm.nih.gov/pubmed/9033462.
Rangaswami J, Bhalla V, Blair JE, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation 2019; 139(16):e840-e878. DOI: 10.1161/CIR.0000000000000664. http://www.ncbi.nlm.nih.gov/pubmed/30852913.
Raphael CE, Finegold JA, Barron AJ, et al. The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: Who benefits the most? Eur Heart J 2015; 36(26):1676–88. DOI: 10.1093/eurheartj/ehv102. http://www.ncbi.nlm.nih.gov/pubmed/25908776.
Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J Med 2002; 347(18):1403–11. http://www.ncbi.nlm.nih.gov/pubmed/12409542.
Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992; 124(4):1017–25. http://www.ncbi.nlm.nih.gov/pubmed/1529875.
Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2015; 373(24):2314–24. DOI: 10.1056/NEJMoa1510774. http://www.ncbi.nlm.nih.gov/pubmed/26549714.
Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: Specialty-related disparities in practice patterns and outcomes. J Am Coll Cardiol 1997; 30(3):733–8. http://www.ncbi.nlm.nih.gov/pubmed/9283533.
Ren S, Newby D, Li SC, et al. Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: A systematic review and meta-analysis. Open Heart 2015; 2(1):e000247. DOI: 10.1136/openhrt-2015-000247. http://www.ncbi.nlm.nih.gov/pubmed/26196020.
Rice H, Say R, Betihavas V. The effect of nurse-led education on hospitalisation, readmission, quality of life and cost in adults with heart failure. A systematic review. Patient Educ Couns 2017; 101(3):363-374. DOI: 10.1016/j.pec.2017.10.002. http://www.ncbi.nlm.nih.gov/pubmed/29102442.
Riley JP, Astin F, Crespo-Leiro MG, et al. Heart Failure Association of the European Society of Cardiology heart failure nurse curriculum. Eur J Heart Fail 2016; 18(7):736–43. DOI: 10.1002/ejhf.568. http://www.ncbi.nlm.nih.gov/pubmed/27220672.
Robert Koch-Institut (RKI). Beschluss der STIKO zur 25. Aktualisierung der COVID-19-Impfempfehlung. Epid Bull 2023(8):3–21. DOI: 10.25646/11151.
Robert Koch-Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2023. Epid Bull 2023(4):3–68. DOI: 10.25646/10829.2.
Roblek T, Deticek A, Leskovar B, et al. Clinical-pharmacist intervention reduces clinically relevant drug-drug interactions in patients with heart failure: A randomized, double-blind, controlled trial. Int J Cardiol 2016; 203:647–52. DOI: 10.1016/j.ijcard.2015.10.206. http://www.ncbi.nlm.nih.gov/pubmed/26580349.
Robson AO, Kerr DN, Ashcroft R, et al. The diuretic response to furosemide. Lancet 1964; 2(7369):1085–8. DOI: 10.1016/s0140-6736(64)92608-x. http://www.ncbi.nlm.nih.gov/pubmed/14207893.
Rogers JG, Patel CB, Mentz RJ, et al. Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial. J Am Coll Cardiol 2017; 70(3):331–41. DOI: 10.1016/j.jacc.2017.05.030. http://www.ncbi.nlm.nih.gov/pubmed/28705314.
Rohde LE, Rover MM, Figueiredo Neto JA, et al. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: A double-blind, multicentre, randomized trial. Eur Heart J 2019; 40(44):3605–12. DOI: 10.1093/eurheartj/ehz554. http://www.ncbi.nlm.nih.gov/pubmed/31424503.
Rohde LE, Zimerman A, Vaduganathan M, et al. Associations Between New York Heart Association Classification, Objective Measures, and Long-term Prognosis in Mild Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol 2023; 8(2):150–8. DOI: 10.1016/j.hrtlng.2021.07.009. http://www.ncbi.nlm.nih.gov/pubmed/36477809.
Rørth R, Jhund PS, Mogensen UM, et al. Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. Diabetes Care 2018; 41(6):1285–91. DOI: 10.2337/dc17-2583. http://www.ncbi.nlm.nih.gov/pubmed/29626073.
Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345(20):1435–43. http://www.ncbi.nlm.nih.gov/pubmed/11794191.
Ruschitzka F, Abraham WT, Singh JP, et al. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med 2013; 369(15):1395–405. DOI: 10.1056/NEJMoa1306687. http://www.ncbi.nlm.nih.gov/pubmed/23998714.
Rutherford JD, Pfeffer MA, Moyé LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994; 90(4):1731–8. DOI: 10.1161/01.cir.90.4.1731. http://www.ncbi.nlm.nih.gov/pubmed/7923656.
Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48(8):1527–37. http://www.ncbi.nlm.nih.gov/pubmed/17045884.
Ryden L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000; 21(23):1967–78. http://www.ncbi.nlm.nih.gov/pubmed/11071803.
Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for reversible airway disease. Cochrane Database Syst Rev 2002(4):CD002992. DOI: 10.1002/14651858.CD002992. http://www.ncbi.nlm.nih.gov/pubmed/12519582.
Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005(4):CD003566. DOI: 10.1002/14651858.CD003566.pub2. http://www.ncbi.nlm.nih.gov/pubmed/16235327.
Santos AB, Kraigher-Krainer E, Bello N, et al. Left ventricular dyssynchrony in patients with heart failure and preserved ejection fraction. Eur Heart J 2014; 35(1):42–7. DOI: 10.1093/eurheartj/eht427. http://www.ncbi.nlm.nih.gov/pubmed/24164863.
Savarese G, Kishi T, Vardeny O, et al. Heart Failure Drug Treatment-Inertia, Titration, and Discontinuation: A Multinational Observational Study (EVOLUTION HF). JACC Heart failure 2023; 11(1):1–14. DOI: 10.1016/j.jchf.2022.08.009. http://www.ncbi.nlm.nih.gov/pubmed/36202739.
Scherer M, Wagner H.O., Lühmann D, et al. Multimorbidität. S3-Leitlinie. AWMF-Register-Nr. 053-047. 2017 (DEGAM-Leitlinie; 20) [cited: 2018-06-06]. http://www.degam.de/files/Inhalte/Leitlinien-Inhalte/Dokumente/DEGAM-S3-Leitlinien/053-047_Multimorbiditaet/053-047l_%20Multimorbiditaet_redakt_24-1-18.pdf.
Schlitt A, Wischmann P, Wienke A, et al. Rehabilitation in Patients With Coronary Heart Disease: Participation and Its Effect on Prognosis. Dtsch Arztebl Int 2015; 112(31-32):527–34. DOI: 10.3238/arztebl.2015.0527. http://www.ncbi.nlm.nih.gov/pubmed/26334980.
Schuchert A, Muto C, Maounis T, et al. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. Europace 2013; 15(1):71–6. DOI: 10.1093/europace/eus247. http://www.ncbi.nlm.nih.gov/pubmed/22927665.
Schulz M, Griese-Mammen N, Anker SD, et al. Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: Results of the PHARM-CHF randomized controlled trial. Eur J Heart Fail 2019; 21(8):1012-1021. DOI: 10.1002/ejhf.1503. http://www.ncbi.nlm.nih.gov/pubmed/31129917.
Schulz M, Krueger K, Schuessel K, et al. Medication adherence and persistence according to different antihypertensive drug classes: A retrospective cohort study of 255,500 patients. Int J Cardiol 2016; 220:668–76. DOI: 10.1016/j.ijcard.2016.06.263. http://www.ncbi.nlm.nih.gov/pubmed/27393848.
Schulze PC, Bogoviku J, Westphal J, et al. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF). Circulation 2022; 146(4):289–98. DOI: 10.1161/CIRCULATIONAHA.122.059038. http://www.ncbi.nlm.nih.gov/pubmed/35766022.
Schwab JO, Bänsch D, Israel C, et al. Stellungnahme zum Einsatz des tragbaren Kardioverter/Defibrillators. Der Kardiologe 2015; 9(2):165–70. DOI: 10.1007/s12181-015-0651-y.
Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic heart failure. Edinburgh: SIGN; 2016 (SIGN Publications; 147). http://www.sign.ac.uk/assets/sign147.pdf.
Senni M, Lopez-Sendon J, Cohen-Solal A, et al. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: Analyses from the VICTORIA trial. ESC Heart Fail 2022; 9(6):3791–803. DOI: 10.1002/ehf2.14050. http://www.ncbi.nlm.nih.gov/pubmed/35880474.
Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: Results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail 2016; 18(9):1193–202. DOI: 10.1002/ejhf.548. http://www.ncbi.nlm.nih.gov/pubmed/27170530.
Servier Deutschland GmbH, Rote Liste/Fachinfo-Service. Procoralan®. Fachinformation. 2015 [cited: 2016-07-17]. http://www.fachinfo.de.
Servier Deutschland GmbH. Information für medizinisches Fachpersonal. Procoralan (Ivabradin) - Neue Kontraindikation und Empfehlungen zur Risikominimierung von kardiovaskulären Ereignissen und schweren Bradykardien. 2014 [cited: 2016-07-17]. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2014/rhb-procoralan.pdf?__blob=publicationFile&v=3.
Shah AM, Pfeffer MA, Hartley LH, et al. Risk of all-cause mortality, recurrent myocardial infarction, and heart failure hospitalization associated with smoking status following myocardial infarction with left ventricular dysfunction. Am. J. Cardiol. 2010; 106(7):911–6. DOI: 10.1016/j.amjcard.2010.05.021. http://www.ncbi.nlm.nih.gov/pubmed/20854949.
Shah AM, Solomon SD. Mechanical Dyssynchrony: A Risk Factor but not a Target. Eur Heart J 2016; 37(1):60–2. DOI: 10.1093/eurheartj/ehv458. http://www.ncbi.nlm.nih.gov/pubmed/26324539.
Shantsila E, Kozieł M, Lip GY. Anticoagulation versus placebo for heart failure in sinus rhythm. Cochrane Database Syst Rev 2021; 5(5):CD003336. DOI: 10.1002/14651858.CD003336.pub4. http://www.ncbi.nlm.nih.gov/pubmed/34002371.
Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol 2015; 115(10):1428–34. DOI: 10.1016/j.amjcard.2015.02.024. http://www.ncbi.nlm.nih.gov/pubmed/25772740.
Sharpe N, Murphy J, Smith H, et al. Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction. Eur Heart J 1990; 11(B Suppl):147–56. DOI: 10.1093/eurheartj/11.suppl_b.147. http://www.ncbi.nlm.nih.gov/pubmed/2142081.
Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: A meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41(9):1529–38. http://www.ncbi.nlm.nih.gov/pubmed/12742294.
Shen L, Kristensen SL, Bengtsson O, et al. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. JACC Heart Fail 2021; 9(4):254–64. DOI: 10.1016/j.jchf.2020.11.009. http://www.ncbi.nlm.nih.gov/pubmed/33549554.
Sherman LG, Liang CS, Baumgardner S, et al. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther 1986; 40(5):587–94. DOI: 10.1038/clpt.1986.228. http://www.ncbi.nlm.nih.gov/pubmed/3533372.
Sidebottom AC, Jorgenson A, Richards H, et al. Inpatient palliative care for patients with acute heart failure: Outcomes from a randomized trial. J Palliat Med 2015; 18(2):134–42. DOI: 10.1089/jpm.2014.0192. http://www.ncbi.nlm.nih.gov/pubmed/25479182.
Siegrist J, Broer M, Junge A. Profil der Lebensqualität chronisch Kranker - Manual. Beltz Test. Göttingen: Beltz; 1996.
Silverman ME, Pressel MD, Brackett JC, et al. Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am. J. Cardiol. 1995; 75(7):460–4. http://www.ncbi.nlm.nih.gov/pubmed/7863989.
Singh JP, Kandala J, Camm AJ. Non-pharmacological modulation of the autonomic tone to treat heart failure. Eur Heart J 2014; 35(2):77–85. DOI: 10.1093/eurheartj/eht436. http://www.ncbi.nlm.nih.gov/pubmed/24174128.
Sipahi I, Chou JC, Hyden M, et al. Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: Meta-analysis of randomized controlled trials. Am Heart J 2012; 163(2):260–7. DOI: 10.1016/j.ahj.2011.11.014. http://www.ncbi.nlm.nih.gov/pubmed/22305845.
Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361(23):2241–51. DOI: 10.1056/NEJMoa0909938. http://www.ncbi.nlm.nih.gov/pubmed/19920051.
Sohaib SM, Finegold JA, Nijjer SS, et al. Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: Evidence from randomized controlled trials. JACC Heart Fail 2015; 3(4):327–36. DOI: 10.1016/j.jchf.2014.11.007. http://www.ncbi.nlm.nih.gov/pubmed/25770400.
Solomon SD, Claggett B, Desai AS, et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial. Circ Heart Fail 2016; 9(3):e002744. DOI: 10.1161/CIRCHEARTFAILURE.115.002744. http://www.ncbi.nlm.nih.gov/pubmed/26915374.
Solomon SD, Jhund PS, Claggett BL, et al. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. JACC Heart Fail 2020; 8(10):811–8. DOI: 10.1016/j.jchf.2020.04.008. http://www.ncbi.nlm.nih.gov/pubmed/32653447.
Solomon SD, McMurray JJ, Anand IS, et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction // Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019; 381(17):1609-1620. DOI: 10.1056/NEJMoa1908655. http://www.ncbi.nlm.nih.gov/pubmed/31475794.
Solomon SD, McMurray JJ, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387(12):1089–98. DOI: 10.1056/NEJMoa2206286. http://www.ncbi.nlm.nih.gov/pubmed/36027570.
Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: The GAD-7. Arch. Intern. Med 2006; 166(10):1092–7. DOI: 10.1001/archinte.166.10.1092. http://www.ncbi.nlm.nih.gov/pubmed/16717171.
Srisuk N, Cameron J, Ski CF, et al. Heart failure family-based education: A systematic review. Patient Educ Couns 2016; 99(3):326–38. DOI: 10.1016/j.pec.2015.10.009. http://www.ncbi.nlm.nih.gov/pubmed/26519992.
Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2017; 4(4):CD001431. DOI: 10.1002/14651858.CD001431.pub5. http://www.ncbi.nlm.nih.gov/pubmed/28402085.
Ständige Impfkommission am Robert Koch Institut (STIKO). Mitteilung der Ständigen Impfkommission am Robert Koch-Institut: Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiologisches Bulletin / Nr. 30. 2005 [cited: 2017-05-10]. http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2005/Ausgabenlinks/30_05.pdf?__blob=publicationFile.
Statistisches Bundesamt (Destatis). Die 10 häufigsten Todesursachen. Sterbefälle insgesamt nach der ICD-10 im Jahr 2015. Herzinsuffizienz (Herzschwäche, Herzmuskelschwäche). 2015 [cited: 2018-07-06]. http://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Gesundheit/Todesursachen/Tabellen/HaeufigsteTodesursachen.html.
Stavrakis S, Garabelli P, Reynolds DW. Cardiac resynchronization therapy after atrioventricular junction ablation for symptomatic atrial fibrillation: A meta-analysis. Europace 2012; 14(10):1490–7. DOI: 10.1093/europace/eus193. http://www.ncbi.nlm.nih.gov/pubmed/22696519.
Steffel J, Robertson M, Singh JP, et al. The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: A subgroup analysis of the EchoCRT trial. Eur Heart J 2015; 36(30):1983–9. DOI: 10.1093/eurheartj/ehv242. http://www.ncbi.nlm.nih.gov/pubmed/26009595.
Steinbeck G, Andresen D, Seidl K, et al. Defibrillator implantation early after myocardial infarction. N. Engl. J Med 2009; 361(15):1427–36. http://www.ncbi.nlm.nih.gov/pubmed/19812399.
Steinberg BA, Al-Khatib SM, Edwards R, et al. Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: Results from a combined analysis of 4 randomized clinical trials. JACC Heart Fail 2014; 2(6):623–9. DOI: 10.1016/j.jchf.2014.06.007. http://www.ncbi.nlm.nih.gov/pubmed/25306452.
Stewart AL, Lynch KJ. Identifying discrepancies in electronic medical records through pharmacist medication reconciliation. J Am Pharm Assoc (Wash. ) 2012; 52(1):59–66. DOI: 10.1331/JAPhA.2012.10123. http://www.ncbi.nlm.nih.gov/pubmed/22257617.
Stewart S, MacIntyre K, Hole DJ, et al. More ‚malignant‘ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3(3):315–22. http://www.ncbi.nlm.nih.gov/pubmed/11378002.
Stork S, Handrock R, Jacob J, et al. Epidemiology of heart failure in Germany: A retrospective database study. Clin Res Cardiol 2017; 106(11):913–22. DOI: 10.1007/s00392-017-1137-7. http://www.ncbi.nlm.nih.gov/pubmed/28748265.
Störk S, Hense HW, Zentgraf C, et al. Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure. A prospective cohort study. Eur J Heart Fail 2008; 10(12):1236–45. http://www.ncbi.nlm.nih.gov/pubmed/18996739.
Stringhini S, Berkman L, Dugravot A, et al. Socioeconomic status, structural and functional measures of social support, and mortality: The British Whitehall II Cohort Study, 1985-2009. Am J Epidemiol 2012; 175(12):1275–83. DOI: 10.1093/aje/kwr461. http://www.ncbi.nlm.nih.gov/pubmed/22534202.
Strocchi E, Malini PL, Valtancoli G, et al. Cough during treatment with angiotensin-converting enzyme inhibitors. Analysis of predisposing factors. Drug Invest 1992; 4:69–72.
Suskin N, Sheth T, Negassa A, et al. Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 37(6):1677–82. http://www.ncbi.nlm.nih.gov/pubmed/11345383.
Sutcliffe P, Connock M, Pulikottil-Jacob R, et al. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: Systematic review and cost-effectiveness model. Health Technol Assess 2013; 17(53):1-vi. DOI: 10.3310/hta17530. http://www.ncbi.nlm.nih.gov/pubmed/24280231.
Swedberg K, Komajda M, Bohm M, et al. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study. J Am Coll Cardiol 2012; 59(22):1938–45. DOI: 10.1016/j.jacc.2012.01.020. http://www.ncbi.nlm.nih.gov/pubmed/22617188.
Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 2010; 376(9744):875–85. DOI: 10.1016/S0140-6736(10)61198-1. http://www.ncbi.nlm.nih.gov/pubmed/20801500.
Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368(13):1210–9. DOI: 10.1056/NEJMoa1214865. http://www.ncbi.nlm.nih.gov/pubmed/23473338.
Swindle JP, Chan WW, Waltman JK, et al. Evaluation of mortality and readmissions following hospitalization with heart failure. Curr Med Res Opin 2016:1–11. DOI: 10.1080/03007995.2016.1205972. http://www.ncbi.nlm.nih.gov/pubmed/27348501.
Täger T, Fröhlich H, Seiz M, et al. READY: Relative efficacy of loop diuretics in patients with chronic systolic heart failure-a systematic review and network meta-analysis of randomised trials. Heart Fail Rev 2019; 24(4):461–72. DOI: 10.1007/s10741-019-09771-8. http://www.ncbi.nlm.nih.gov/pubmed/30874955.
Takagi H, Umemoto T. Similar Survival After Repair vs Replacement for Ischemic Mitral Regurgitation. Semin. Thorac. Cardiovasc. Surg. 2016; 28(4):748–56. DOI: 10.1053/j.semtcvs.2016.09.001. http://www.ncbi.nlm.nih.gov/pubmed/28417860.
Tang AS, Wells GA, Talajic M, et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure. N. Engl. J Med 2010; 363(25):2385–95. DOI: 10.1056/NEJMoa1009540. http://www.ncbi.nlm.nih.gov/pubmed/21073365.
Tang YD, Katz SD. Anemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation 2006; 113(20):2454–61. http://www.ncbi.nlm.nih.gov/pubmed/16717164.
Taylor KS, Verbakel JY, Feakins BG, et al. Diagnostic accuracy of point-of-care natriuretic peptide testing for chronic heart failure in ambulatory care: Systematic review and meta-analysis. BMJ 2018; 361:k1450. http://www.ncbi.nlm.nih.gov/pubmed/29785952.
Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014(4):CD003331. DOI: 10.1002/14651858.CD003331.pub4. http://www.ncbi.nlm.nih.gov/pubmed/24771460.
Taylor RS, Walker S, Smart NA, et al. Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: An individual patient data meta-analysis of randomised trials. Eur J Heart Fail 2018; 20(12):1735-1743. DOI: 10.1002/ejhf.1311. http://www.ncbi.nlm.nih.gov/pubmed/30255969.
The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336(8):525–33. http://www.ncbi.nlm.nih.gov/pubmed/9036306.
The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327(10):685–91. http://www.ncbi.nlm.nih.gov/pubmed/1463530.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325(5):293–302. http://www.ncbi.nlm.nih.gov/pubmed/2057034.
Tiller D, Russ M, Greiser KH, et al. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS. One. 2013; 8(3):e59225. DOI: 10.1371/journal.pone.0059225. http://www.ncbi.nlm.nih.gov/pubmed/23555000.
Toussaint A, Löwe B, Brähler E, et al. The Somatic Symptom Disorder - B Criteria Scale (SSD-12): Factorial structure, validity and population-based norms. J Psychosom Res 2017; 97:9–17. DOI: 10.1016/j.jpsychores.2017.03.017. http://www.ncbi.nlm.nih.gov/pubmed/28606504.
Toussaint A, Riedl B, Kehrer S, et al. Validity of the Somatic Symptom Disorder-B Criteria Scale (SSD-12) in primary care. Fam Pract 2018; 35(3):342–7. DOI: 10.1093/fampra/cmx116. http://www.ncbi.nlm.nih.gov/pubmed/29145575.
Travers B, O‘Loughlin C, Murphy NF, et al. Fluid restriction in the management of decompensated heart failure: No impact on time to clinical stability. J Card Fail 2007; 13(2):128–32. http://www.ncbi.nlm.nih.gov/pubmed/17395053.
Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail 2016; 18(7):744–58. DOI: 10.1002/ejhf.600. http://www.ncbi.nlm.nih.gov/pubmed/27358242.
Tsuyuki RT, Al Hamarneh YN, Jones CA, et al. The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial. J Am Coll Cardiol 2016; 67(24):2846–54. DOI: 10.1016/j.jacc.2016.03.528. http://www.ncbi.nlm.nih.gov/pubmed/27058907.
Tu R-H, Zeng Z-Y, Zhong G-Q, et al. Effects of exercise training on depression in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials. Eur J Heart Fail 2014; 16(7):749–57. DOI: 10.1002/ejhf.101. http://www.ncbi.nlm.nih.gov/pubmed/24797230.
Unverzagt S, Meyer G, Mittmann S, et al. Improving Treatment Adherence in Heart Failure. Dtsch Arztebl Int 2016; 113(25):423–30. DOI: 10.3238/arztebl.2016.0423. http://www.ncbi.nlm.nih.gov/pubmed/27397013.
Upadhyay GA, Choudhry NK, Auricchio A, et al. Cardiac resynchronization in patients with atrial fibrillation: A meta-analysis of prospective cohort studies. J Am Coll Cardiol 2008; 52(15):1239–46. http://www.ncbi.nlm.nih.gov/pubmed/18926327.
Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet 2022; 400(10354):757–67. DOI: 10.1016/S0140-6736(22)01429-5. http://www.ncbi.nlm.nih.gov/pubmed/36041474.
Valentini L, Volkert D, Schütz T, et al. Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM). Aktuel Ernahrungsmed 2013; 38(02):97–111. DOI: 10.1055/s-0032-1332980.
Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: A systematic review and meta-analysis of the literature. Eur Heart J 2015; 36(28):1831–8. DOI: 10.1093/eurheartj/ehv143. http://www.ncbi.nlm.nih.gov/pubmed/25939649.
van der Heijden AC, Borleffs CJ, Buiten MS, et al. The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications. Heart Rhythm 2015; 12(6):1169–76. DOI: 10.1016/j.hrthm.2015.02.035. http://www.ncbi.nlm.nih.gov/pubmed/25749138.
van Spall HG, Rahman T, Mytton O, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: A systematic review and network meta-analysis. Eur J Heart Fail 2017; 19(11):1427–43. DOI: 10.1002/ejhf.765. http://www.ncbi.nlm.nih.gov/pubmed/28233442.
van Veldhuisen DJ, Ponikowski P, van der Meer P, et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. Circulation 2017; 136(15):1374–83. DOI: 10.1161/CIRCULATIONAHA.117.027497. http://www.ncbi.nlm.nih.gov/pubmed/28701470.
van Weel C, König-Zahn C, Touw-Otten F. Measuring functional health status with the COOP/WONCA charts: A manual. 2nd ed. Groningen: Noordelijke Centrum voor Gezondheidsvraagstukken; 2012.
Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997; 29(2):229–36. DOI: 10.1016/s0735-1097(96)00489-5. http://www.ncbi.nlm.nih.gov/pubmed/9014971.
Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: The PARADIGM-HF trial. Eur J Heart Fail 2019; 21(3):337–41. DOI: 10.1002/ejhf.1402. http://www.ncbi.nlm.nih.gov/pubmed/30741494.
Vardeny O, Claggett B, Packer M, et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: The PARADIGM-HF trial. Eur J Heart Fail 2016; 18(10):1228–34. DOI: 10.1002/ejhf.580. http://www.ncbi.nlm.nih.gov/pubmed/27283779.
Vardeny O, Claggett B, Udell JA, et al. Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial. JACC Heart Fail 2016; 4(2):152–8. DOI: 10.1016/j.jchf.2015.10.012. http://www.ncbi.nlm.nih.gov/pubmed/26746371.
Vasan RS, Xanthakis V, Lyass A, et al. Epidemiology of Left Ventricular Systolic Dysfunction and Heart Failure in the Framingham Study: An Echocardiographic Study Over 3 Decades. JACC. Cardiovasc Imaging 2018; 11(1):1–11. DOI: 10.1016/j.jcmg.2017.08.007. http://www.ncbi.nlm.nih.gov/pubmed/28917679.
Vedel I, Khanassov V. Transitional Care for Patients With Congestive Heart Failure: A Systematic Review and Meta-Analysis. Ann Fam Med 2015; 13(6):562–71. DOI: 10.1370/afm.1844. http://www.ncbi.nlm.nih.gov/pubmed/26553896.
Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364(17):1607–16. http://www.ncbi.nlm.nih.gov/pubmed/21463150.
Velazquez EJ, Lee KL, Jones RH, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. N Engl J Med 2016; 374(16):1511–20. DOI: 10.1056/NEJMoa1602001. http://www.ncbi.nlm.nih.gov/pubmed/27040723.
Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med 2019; 380(6):539–48. DOI: 10.1056/NEJMoa1812851. http://www.ncbi.nlm.nih.gov/pubmed/30415601.
Verordnungseinschränkungen für Ivabradin (PROCORALAN) in Frankreich. Arznei-Telegramm 2016; 48(6):54.
Vidán MT, Blaya-Novakova V, Sánchez E, et al. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. Eur J Heart Fail 2016; 18(7):869–75. DOI: 10.1002/ejhf.518. http://www.ncbi.nlm.nih.gov/pubmed/27072307.
Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev 2013(5):CD005351. DOI: 10.1002/14651858.CD005351.pub3. http://www.ncbi.nlm.nih.gov/pubmed/23728654.
Vizzardi E, D‘Aloia A, Giubbini R, et al. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am. J. Cardiol. 2010; 106(9):1292–6. DOI: 10.1016/j.amjcard.2010.06.052. http://www.ncbi.nlm.nih.gov/pubmed/21029826.
Voelker W. Strukturierter Datensatz zur Befunddokumentation in der Echokardiographie - Version 2004. Z Kardiol 2004; 93(12):987–1004. http://www.ncbi.nlm.nih.gov/pubmed/15599575.
Vogels RL, Scheltens P, Schroeder-Tanka JM, et al. Cognitive impairment in heart failure: A systematic review of the literature. Eur J Heart Fail 2007; 9(5):440–9. http://www.ncbi.nlm.nih.gov/pubmed/17174152.
Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: A multinational randomized trial. Nat Med 2022; 28(3):568–74. DOI: 10.1080/10543406.2017.1397007. http://www.ncbi.nlm.nih.gov/pubmed/35228754.
Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: Primary results of the randomised TRANSITION study. Eur J Heart Fail 2019; 21(8):998–1007. DOI: 10.1002/ejhf.1498. http://www.ncbi.nlm.nih.gov/pubmed/31134724.
Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013(8):CD005151. DOI: 10.1002/14651858.CD005151.pub2. http://www.ncbi.nlm.nih.gov/pubmed/23922186.
Waltenberger J, Schöne-Seifert B, Friedrich DR, et al. Verantwortlicher Umgang mit ICDs. Der Kardiologe 2017; 11(5):383–97. DOI: 10.1007/s12181-017-0185-6.
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6):473–83. http://www.ncbi.nlm.nih.gov/pubmed/1593914.
Ware JJ, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34(3):220–33. http://www.ncbi.nlm.nih.gov/pubmed/8628042.
Welte T, Kohnlein T. Global and local epidemiology of community-acquired pneumonia: The experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009; 30(2):127–35. DOI: 10.1055/s-0029-1202941. http://www.ncbi.nlm.nih.gov/pubmed/19296412.
Wesemann T, Nullmann H, Pflug MA, et al. Pneumonia severity, comorbidity and 1-year mortality in predominantly older adults with community-acquired pneumonia: A cohort study. BMC Infect Dis 2015; 15:2. DOI: 10.1186/s12879-014-0730-x. http://www.ncbi.nlm.nih.gov/pubmed/25566688.
Westaby S. Non-transplant surgery for heart failure. Heart 2000; 83(5):603–10. http://www.ncbi.nlm.nih.gov/pubmed/10768919.
Westaby S. Surgery for heart failure: Now something for everyone? Heart Fail Clin 2007; 3(2):139–57. http://www.ncbi.nlm.nih.gov/pubmed/17643919.
Westerdahl AK, Sutton R, Frykman V. Defibrillator patients should not be denied a peaceful death. Int J Cardiol 2015; 182:440–6. DOI: 10.1016/j.ijcard.2015.01.012. http://www.ncbi.nlm.nih.gov/pubmed/25597981.
Whellan DJ, Goodlin SJ, Dickinson MG, et al. End-of-life care in patients with heart failure. J Card Fail 2014; 20(2):121–34. DOI: 10.1016/j.cardfail.2013.12.003. http://www.ncbi.nlm.nih.gov/pubmed/24556532.
White WB, Saag KG, Becker MA, et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 2018; 378(13):1200–10. DOI: 10.1056/NEJMoa1710895. http://www.ncbi.nlm.nih.gov/pubmed/29527974.
Wilensky RL, Yudelman P, Cohen AI, et al. Serial electrocardiographic changes in idiopathic dilated cardiomyopathy confirmed at necropsy. Am. J. Cardiol. 1988; 62(4):276–83. http://www.ncbi.nlm.nih.gov/pubmed/3400606.
Willemsen D, Cordes C, Bjarnason-Wehrens B, et al. Rehabilitationsstandards für die Anschlussheilbehandlung und allgemeine Rehabilitation von Patienten mit einem Herzunterstützungssystem (VAD - ventricular assist device). Clin Res Cardiol. Suppl 2016; 11 Suppl 1:2–49. DOI: 10.1007/s11789-015-0077-x. http://www.ncbi.nlm.nih.gov/pubmed/26882905.
Wilson JR, Reichek N, Dunkman WB, et al. Effect of diuresis on the performance of the failing left ventricle in man. Am J Med 1981; 70(2):234–9. http://www.ncbi.nlm.nih.gov/pubmed/7468610.
Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35(37):2541–619. DOI: 10.1093/eurheartj/ehu278. http://www.ncbi.nlm.nih.gov/pubmed/25173339.
Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. http://www.ncbi.nlm.nih.gov/pubmed/30415602.
Woods B, Hawkins N, Mealing S, et al. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart 2015; 101(22):1800–6. DOI: 10.1136/heartjnl-2015-307634. http://www.ncbi.nlm.nih.gov/pubmed/26269413.
Wrobel K, Stevens SR, Jones RH, et al. Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction: Results From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. Circulation 2015; 132(8):720–30. DOI: 10.1161/CIRCULATIONAHA.114.014932. http://www.ncbi.nlm.nih.gov/pubmed/26304663.
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16):e147-e239. DOI: 10.1016/j.jacc.2013.05.019. http://www.ncbi.nlm.nih.gov/pubmed/23747642.
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136(6):e137-e161. DOI: 10.1161/CIR.0000000000000509. http://www.ncbi.nlm.nih.gov/pubmed/28455343.
Yap SC, Schaer BA, Bhagwandien RE, et al. Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart 2014; 100(15):1188–92. DOI: 10.1136/heartjnl-2014-305535. http://www.ncbi.nlm.nih.gov/pubmed/24993502.
Yeo TJ, Yeo PS, Hadi FA, et al. Single-dose intravenous iron in Southeast Asian heart failure patients: A pilot randomized placebo-controlled study (PRACTICE-ASIA-HF). ESC Heart Fail 2018; 5(2):344–53. DOI: 10.1002/ehf2.12250. http://www.ncbi.nlm.nih.gov/pubmed/29345426.
Yu CM, Zhang Q, Yip GW, et al. Diastolic and systolic asynchrony in patients with diastolic heart failure: A common but ignored condition. J Am Coll Cardiol 2007; 49(1):97–105. DOI: 10.1016/j.jacc.2006.10.022. http://www.ncbi.nlm.nih.gov/pubmed/17207728.
Zannad F, Ferrari GM de, Tuinenburg AE, et al. Chronic vagal stimulation for the treatment of low ejection fraction heart failure: Results of the NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) randomized controlled trial. Eur Heart J 2015; 36(7):425–33. DOI: 10.1093/eurheartj/ehu345. http://www.ncbi.nlm.nih.gov/pubmed/25176942.
Zannad F, Ferreira JP, Pocock SJ, et al. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Trial. Circulation 2021; 143(4):310–21. DOI: 10.1161/CIRCULATIONAHA.120.051685. http://www.ncbi.nlm.nih.gov/pubmed/33095032.
Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364(1):11–21. DOI: 10.1056/NEJMoa1009492. http://www.ncbi.nlm.nih.gov/pubmed/21073363.
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393(10166):31–9. DOI: 10.1016/S0140-6736(18)32590-X. http://www.ncbi.nlm.nih.gov/pubmed/30424892.
Zentgraf C. Zum Stand der Versorgungssituation der chronischen Herzinsuffizienz. Eine prospektive Analyse an 1054 konsekutiv rekrutierten Patienten am Interdisziplinären Herzinsuffizienzregister Würzburg. Dissertation zu Erlangung der Doktorwürde der Medizinischen Fakultät der Bayerischen Julius-Maximilians-Universität zu Würzburg. Würzburg: Med. Fakultät der Bayerischen Julius-Maximilians-Universität; 2007.
Zieschang M. Behandlung der Hyperkaliämie bei Erwachsenen. AVP 2023; 50(1):14–29.
Ziff OJ, Lane DA, Samra M, et al. Safety and efficacy of digoxin: Systematic review and meta-analysis of observational and controlled trial data. BMJ 2015; 351:h4937. http://www.ncbi.nlm.nih.gov/pubmed/26374771.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22):2117–28. DOI: 10.1056/NEJMoa1504720. http://www.ncbi.nlm.nih.gov/pubmed/26378978.
Zipes DP, Wyse DG, Friedman PL. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 1997; 337(22):1576–83. DOI: 10.1056/NEJM199711273372202. http://www.ncbi.nlm.nih.gov/pubmed/9411221.
Zuccala G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Heart J 2005; 26(3):226–33. http://www.ncbi.nlm.nih.gov/pubmed/15618043.
Zuccala G, Pedone C, Cesari M, et al. The effects of cognitive impairment on mortality among hospitalized patients with heart failure. Am J Med 2003; 115(2):97–103. http://www.ncbi.nlm.nih.gov/pubmed/12893394.
Zugck C, Nelles M, Frankenstein L, et al. Telemedizin reduziert bei Patienten mit chronischer Herzinsuffizienz zusätzlich zur optimierten medikamentösen Therapie signifikant die Krankenhausverweildauer. Clin Res Cardiol 2008; 97(1 Suppl):V1734-V1734.
Zusterzeel R, Selzman KA, Sanders WE, et al. Cardiac resynchronization therapy in women: US Food and Drug Administration meta-analysis of patient-level data. JAMA Intern Med 2014; 174(8):1340–8. DOI: 10.1001/jamainternmed.2014.2717. http://www.ncbi.nlm.nih.gov/pubmed/25090172.
Zwisler A-D, Norton RJ, Dean SG, et al. Home-based cardiac rehabilitation for people with heart failure: A systematic review and meta-analysis. Int J Cardiol 2016; 221:963–9. DOI: 10.1016/j.ijcard.2016.06.207. http://www.ncbi.nlm.nih.gov/pubmed/27441476.

NVL Chronische Herzinsuffizienz, Version 4.0, 2023

Mehr zur NVL Chronische Herzinsuffizienz

Weitere Materialien

Flyer: Was ist wichtig? Was ist neu?
Die Kernaussagen der NVL für Ärztinnen und Ärzte zusammengefasst.
Foliensatz
Für Präsentationen zu den NVL bei Kongressen.

Patientenblätter

Herzschwäche - Gemeinsam entscheiden
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Bedeutung von seelischen Belastungen
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Warum Bewegung?
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Regelmäßige Gewichtskontrolle?
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Ernährungstipps
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Warum Rauchstopp hilft
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Wichtigste Medikamente
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Begleiterkrankungen - was ist wichtig
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Behandlung am Lebensende
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Brauche ich einen CRT-Schrittmacher?
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Darf ich Auto fahren?
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Empfohlene Impfungen
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Entscheidungshilfe: CRT-Schrittmacher mit oder ohne Defibrillator?
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Entscheidungshilfe: Soll ich mir einen ICD einsetzen lassen?
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Information für Angehörige
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Leere Batterie: Brauche ich den ICD noch?
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Notfall erkennen
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Vorsicht bei bestimmten Medikamenten
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Vorsorgevollmacht und Patientenverfügung
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Was tun bei erhaltener Pumpfunktion?
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de
Herzschwäche - Neue Medikamente richtig einnehmen
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de

Patientenleitlinie

Patientenleitlinie Herzschwäche
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de

Kurzinformationen

Herzschwäche – was für Sie wichtig ist
Sie werden weitergeleitet auf unsere Seite Patienten-Information.de

Bitte beachten Sie, dass nur die unter www.leitlinien.de enthaltenen Dokumente des Programms für Nationale VersorgungsLeitlinien durch die Träger des NVL-Programms autorisiert und damit gültig sind. Bei NVL-Dokumenten, die Sie von anderen Webseiten beziehen, übernehmen wir keine Verantwortung für deren Gültigkeit.

PDF-Version

Langfassung
PDF zum Download
Kurzfassung
PDF zum Download

Archiv

Das Archiv enthält abgelaufene, zurückgezogene Dokumente zur Nationalen Versorgungsleitlinie Chronische Herzinsuffizienz.

Langfassung, Version 4, Konsultation
ersetzt durch Version 4.0 am 12. Dezember 2023
Langfassung, 3. Auflage, Version 3
ersetzt durch Version 4.0, Dezember 2023
Leitlinienreport, 3. Auflage, Version 3
ersetzt durch Version 4.0 im Dezember 2023.
Langfassung, 3. Auflage, Version 2
ersetzt durch 3. Auflage, Version 3, September 2021. Begründung: Einfügung des Abschnitts Therapieintensivierung bei fortbestehender Symptomatik unter Basistherapie, redaktionelle Korrekturen
Langfassung, 3. Auflage, Amendment, Konsultation
wird ersetzt durch 3. Auflage, Version 3, September 2021
Langfassung, 3. Auflage, Version 1
ersetzt durch Version 2, Mai 2020. Begründung: Einfügung eines Abschnitts zu SGLT2-Inhibitoren
Langfassung, 3. Auflage, Konsultation
ersetzt durch 3. Auflage, Version 1 am 22. Oktober 2019
Langfassung, 2. Auflage, Version 3
ersetzt durch 3. Auflage
Langfassung, 2. Auflage, Version 2
ersetzt durch Version 3, April 2018. Begründung: redaktionelle Korrekturen
Langfassung, 2. Auflage, Version 1
ersetzt durch Version 2 im September 2017. Begründung: redaktionelle Korrekturen
Langfassung, 2. Auflage, Konsultation
ersetzt durch 2. Auflage, Version 1 am 31. August 2017
Langfassung, 1. Auflage, Version 7
ersetzt durch 2. Auflage
Langfassung, 1. Auflage, Version 1.5
ersetzt durch Version 7, August 2013. Begründung: Grundsätzliche Änderung der vorgegebenen Gültigkeit aller NVL von vier auf fünf Jahre, Einführung neuer Versionsnummerierung, Ergänzung der DOI sowie redaktionelle Änderungen
Langfassung, 1. Auflage, Version 1.4
ersetzt durch Version 1.5, März 2012. Begründung: Redaktionelle Änderungen
Langfassung, 1. Auflage, Version 1.3
ersetzt durch Version 1.4, Mai 2011. Begründung: Redaktionelle Änderungen
Langfassung, 1. Auflage, Version 1.2
ersetzt durch Version 1.3, November 2010. Begründung: Redaktionelle Änderungen
Langfassung, 1. Auflage, Version 1.1
ersetzt durch Version 1.2, Juli 2010. Begründung: Ergänzungen bei den Vorschlägen für die Qualitätsindikatoren in Kapitel 14, Umformulierung von Empfehlung 5-13
Langfassung, 1. Auflage, Version 1.0
ersetzt durch Version 1.1, März 2010. Begründung: Textänderungen in Abbildung 1 und bei den Zielen
Langfassung, 1. Auflage, Konsultationsentwurf, Version 1.0
ersetzt durch Version 1.0, Dezember 2009. Begründung: Ende der Konsultationsphase am 24. Juni 2009
Kurzfassung, 2. Auflage, Version 2
ersetzt durch 3. Auflage
Kurzfassung, 2. Auflage, Version 1
ersetzt durch Version 2, April 2018. Begründung: redaktionelle Korrekturen
Kurzfassung, 1. Auflage, Version 7
ersetzt durch 2. Auflage
Kurzfassung, 1. Auflage, Version 1.5
ersetzt durch Version 7, August 2013. Begründung: Grundsätzliche Änderung der vorgegebenen Gültigkeit aller NVL von vier auf fünf Jahre, Einführung neuer Versionsnummerierung, Ergänzung der DOI sowie redaktionelle Änderungen
Kurzfassung, 1. Auflage, Version 1.4
ersetzt durch Version 1.5, März 2012. Begründung: Redaktionelle Änderungen
Kurzfassung, 1. Auflage, Version 1.3
ersetzt durch Version 1.4, Mai 2011. Begründung: Redaktionelle Änderungen
Kurzfassung, 1. Auflage, Version 1.2
ersetzt durch Version 1.3, November 2010. Begründung: Redaktionelle Änderungen
Kurzfassung, 1. Auflage, Version 1.1
ersetzt durch Version 1.2, Juli 2010. Begründung: Ergänzungen bei den Vorschlägen für die Qualitätsindikatoren in Kapitel 14, Umformulierung von Empfehlung 5-13
Leitlinienreport, 3. Auflage, Version 2
ersetzt durch 3. Auflage, Version 3 im September 2021. Begründung: Ergänzung der Dokumentation der systematischen Evidenzaufarbeitung und Einfügung der Evidenztabellen zu SGLT2-Inhibitoren, Aktualisierung und Ergänzung der Autorenliste, des Interessenkonfliktmanagements und der Stimmenthaltungen
Leitlinienreport zum Amendment, 3. Auflage, Konsultation
wird ersetzt durch 3. Auflage, Version 3, September 2021
Leitlinienreport, 3. Auflage, Version 1
ersetzt durch Version 2, Mai 2020. Begründung: Einfügung eines Abschnitts zu SGLT2-Inhibitoren
Leitlinienreport, 3. Auflage, Konsultation
ersetzt durch 3. Auflage, Version 1 am 22. Oktober 2019
Leitlinienreport, 2. Auflage, Version 3
ersetzt durch 3. Auflage
Leitlinienreport, 2. Auflage, Version 2
ersetzt durch Version 3, April 2018. Begründung: redaktionelle Korrekturen
Leitlinienreport, 2. Auflage, Version 1
ersetzt durch Version 2 im September 2017. Begründung: Korrektur der Empfehlungsnummerierung in Anhang 3 (Abstimmungsergebnis der Empfehlungen); redaktionelle Korrekturen
Leitlinienreport, 2. Auflage, Konsultation
ersetzt durch 2. Auflage, Version 1 am 31. August 2017
Leitlinien-Report. 1. Auflage, Version 2
ersetzt durch 2. Auflage
Leitlinien-Report, 1. Auflage, Version 1.0
ersetzt durch Version 2, August 2013. Begründung: Grundsätzliche Änderung der vorgegebenen Gültigkeit aller NVL von vier auf fünf Jahre, Einführung neuer Versionsnummerierung, Ergänzung der DOI sowie redaktionelle Änderungen
PatientenLeitlinie, 2. Auflage, Konsultation
ersetzt durch 2. Auflage, Version 1, Oktober 2020
PatientenLeitlinie, 1. Auflage, Version 1
ersetzt durch 2. Auflage
PatientenLeitlinie, 1. Auflage, Konsultationsentwurf, Version 1
ersetzt durch Finalfassung. Begründung: Ende der Konsultationsphase am 12. Oktober 2010

Hinweise und Kommentare

Sie haben Hinweise und Kommentare zu unserem Internetangebot?

Literatur

Weitere Materialien

Patientenblätter

Patientenleitlinie

Kurzinformationen

Wichtiger Hinweis

PDF-Version

Archiv

Aktuelles

Angebote des ÄZQ

Kontakt

Service

Newsletter